[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Exhibit 10.25
EXECUTION COPY
 
PURCHASE OPTION AGREEMENT
by and among
DYNAVAX TECHNOLOGIES CORPORATION,
SYMPHONY DYNAMO HOLDINGS LLC
and
SYMPHONY DYNAMO, INC.
 
Dated as of April 18, 2006
 
     
 
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

 

--------------------------------------------------------------------------------

 

TABLE OF CONTENTS

              Page
Section 1. Grant of Purchase Option
    2  
 
       
Section 2. Exercise of Purchase Option
    3  
 
       
Section 2A. Put Option
    6  
 
       
Section 3. Dynavax Representations, Warranties and Covenants
    7  
 
       
Section 4. Holdings Representations, Warranties and Covenants
    9  
 
       
Section 5. Symphony Dynamo Representations, Warranties and Covenants
    13  
 
       
Section 6. Notice of Material Event
    21  
 
       
Section 7. Assignment; Transfers; Legend
    21  
 
       
Section 8. Costs and Expenses; Payments
    22  
 
       
Section 9. Expiration; Termination of Agreement
    22  
 
       
Section 10. Survival; Indemnification
    22  
 
       
Section 11. No Petition
    25  
 
       
Section 12. Third-Party Beneficiary
    25  
 
       
Section 13. Notices
    25  
 
       
Section 14. Governing Law; Consent to Jurisdiction and Service of Process
    27  
 
       
SECTION 15. WAIVER OF JURY TRIAL
    27  
 
       
Section 16. Entire Agreement
    27  
 
       
Section 17. Amendment; Successors; Counterparts
    27  
 
       
Section 18. Specific Performance
    28  
 
       
Section 19. Severability
    28  
 
       
Section 20. Tax Reporting
    28  
 
       
Schedule I Quarterly Price Table
       
 
       
Annex A Certain Definitions
       
 
       
Exhibit 1 Purchase Option Exercise Notice
       
 
       
Exhibit 2 Form of opinion of Cooley Godward LLP
       

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

 

--------------------------------------------------------------------------------

 

PURCHASE OPTION AGREEMENT
          This PURCHASE OPTION AGREEMENT (this “Agreement”) is entered into as
of April 18, 2006 (the “Closing Date”) by and among DYNAVAX TECHNOLOGIES
CORPORATION, a Delaware corporation (“Dynavax”), SYMPHONY DYNAMO HOLDINGS LLC, a
Delaware limited liability company (“Holdings”), and SYMPHONY DYNAMO, INC., a
Delaware corporation (“Symphony Dynamo”). Capitalized terms used herein and not
defined herein shall have the meanings assigned to such terms in Annex A
attached hereto.
PRELIMINARY STATEMENT
          WHEREAS, Dynavax and Holdings have entered into a Technology License
Agreement pursuant to which Dynavax has granted Holdings an exclusive license
(the “License”) to the use of certain intellectual property related to the
Programs owned or controlled by Dynavax;
          WHEREAS, contemporaneously with the execution of this Agreement,
Dynavax, Holdings and Symphony Dynamo are entering into a Novated and Restated
Technology License Agreement, pursuant to which, among other things, Holdings
will assign by way of novation the License to Symphony Dynamo;
          WHEREAS, Dynavax and Holdings have entered into a Research and
Development Agreement pursuant to which Dynavax has agreed, among other things,
to perform, on behalf of Holdings, research and development of the Programs;
          WHEREAS, contemporaneously with the execution of this Agreement,
Dynavax, Holdings and Symphony Dynamo are entering into an Amended and Restated
Research and Development Agreement, pursuant to which, among other things,
Holdings will assign its rights and obligations under the Research and
Development Agreement to Symphony Dynamo;
          WHEREAS, contemporaneously with the execution of this Agreement, in
order to fund such research and development, institutional investors are
committing to invest $50,000,000 in Holdings (the “Financing”) in exchange for
membership interests in Holdings and for a warrant to purchase up to a total of
2,000,000 shares of Dynavax Common Stock (the “Warrant”), to be initially issued
to Holdings, and Holdings will agree to contribute the net proceeds of the
Financing to Symphony Dynamo;
          WHEREAS, Holdings desires, in consideration for the Warrant, to grant
Dynavax an option to purchase all of the Common Stock of Symphony Dynamo and any
other Equity Securities issued by Symphony Dynamo (together, the “Symphony
Dynamo Equity Securities”) owned, or hereinafter acquired, by Holdings on the
terms described in this Agreement; and
          WHEREAS, Symphony Dynamo and Holdings have determined that it is in
each of its best interest to perform and comply with certain agreements and
covenants relating to each of its ongoing operations contained in this
Agreement;
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

 

--------------------------------------------------------------------------------

 

          NOW, THEREFORE, in consideration of the foregoing and for other good
and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto (the “Parties”) agree as follows:
          Section 1. Grant of Purchase Option.
          (a) Holdings hereby grants to Dynavax an exclusive option (the
“Purchase Option”) to purchase all, but not less than all, of the outstanding
Symphony Dynamo Equity Securities owned or hereinafter acquired by Holdings, in
accordance with the terms of this Agreement.
          (b) Symphony Dynamo hereby covenants and agrees that all Symphony
Dynamo Equity Securities issued by Symphony Dynamo at any time prior to the
expiration of the Term (including to Holdings on, prior to, or after the date
hereof or to any other Person at any time whatsoever, in all cases prior to the
expiration of the Term) shall be subject to a purchase option on the same terms
as the Purchase Option (except as provided by the immediately following
sentence) and all of the other terms and conditions of this Agreement without
any additional action on the part of Dynavax or Holdings. Further, to the extent
Symphony Dynamo shall issue any Symphony Dynamo Equity Securities (including any
issuance in respect of a transfer of Symphony Dynamo Equity Securities by any
holder thereof, including Holdings) after the date hereof to any Person
(including Holdings) (any issuance of such Symphony Dynamo Equity Securities
being subject to the prior written consent of Dynavax as set forth in
Sections 5(c) and 7(b) hereof, as applicable), Symphony Dynamo hereby covenants
and agrees that it shall cause such Symphony Dynamo Equity Securities to be
subject to the Purchase Option without the payment of, or any obligation to pay,
any additional consideration in respect of such Symphony Dynamo Equity
Securities by Dynavax, Symphony Dynamo or any Symphony Dynamo Subsidiary to the
Person(s) acquiring such subsequently issued Symphony Dynamo Equity Securities,
the Parties acknowledging and agreeing that the sole consideration payable by
Dynavax pursuant to this Agreement for all of the outstanding Symphony Dynamo
Equity Securities now or hereinafter owned by any Person shall be the Purchase
Price.
          (c) Dynavax’s right to exercise the Purchase Option granted hereby is
subject to the following conditions:
     (i) The Purchase Option may only be exercised for the purchase of all, and
not less than all, of Holdings’ Symphony Dynamo Equity Securities;
          (ii) The Purchase Option may only be exercised a single time;
     (iii) Except as expressly provided in Section 1(c)(iv), the Purchase Option
may be exercised only during the period (the “Purchase Option Period”)
commencing on and including April 18, 2007, (the “Purchase Option Commencement
Date”) and ending on and including the earlier of (x) April 18, 2011 and (y) the
[ * ] day immediately following the first date on which an internally prepared,
unaudited, balance sheet of Symphony Dynamo (prepared in accordance with GAAP)
is delivered to Dynavax stating that the aggregate amount of (A) cash and cash
equivalents held by Symphony Dynamo and (B)
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

2

--------------------------------------------------------------------------------

 

cash that will be received in connection with a pending Funding Notice provided
by Holdings to the Investors pursuant to the Funding Agreement is less than [ *
]; and
     (iv) In the event that Holdings terminates the Amended and Restated
Research and Development Agreement pursuant to Section 17.2 thereof, Dynavax [ *
] to notify Holdings of its exercise of the Purchase Option under the terms of
this Agreement. Such exercise of the Purchase Option by Dynavax may occur prior
to the Purchase Option Commencement Date (an “Early Purchase Option Exercise”).
          Section 2. Exercise of Purchase Option.
          (a) Exercise Notice. Dynavax may exercise the Purchase Option only by
delivery of a notice in the form attached hereto as Exhibit 1 (the “Purchase
Option Exercise Notice”) during the Purchase Option Period. The Purchase Option
Exercise Notice shall be delivered on a Business Day to Holdings and Symphony
Dynamo and shall be irrevocable once delivered. The date on which the Purchase
Option Exercise Notice is first delivered to Holdings and Symphony Dynamo is
referred to as the “Purchase Option Exercise Date.” The Purchase Option Exercise
Notice shall contain (1) an estimated date for the settlement of the Purchase
Option (the “Purchase Option Closing”), which date shall be estimated in
accordance with this Section 2(a), (2) the Purchase Price, determined in
accordance with Section 2(b) hereof, and (3) if Dynavax intends to pay part of
the Purchase Price in Dynavax Common Stock, notice of such intent, the number of
shares to be transferred as such purchase price, the valuation thereof and the
percentage such portion bears to (A) the Purchase Price, and (B) the total
amount of Dynavax Common Stock then issued and outstanding (which shall be no
greater percentages than are permitted under Section 2(c)). Such notice and
election shall be irrevocable once given and made. If, during the period
following delivery of the Purchase Option Exercise Notice, the amount of cash
and cash equivalents held by Symphony Dynamo is an amount less than or equal to
[ * ] then Symphony Dynamo shall cease payment of any amounts owed to Dynavax in
respect of its activities pursuant to the Amended and Restated Research and
Development Agreement, but shall continue to pay amounts owed to all other
Persons. The date of the Purchase Option Closing (the “Purchase Option Closing
Date”) shall be determined as follows:
     (i) If Dynavax elects to pay the entire Purchase Price in cash, the
Purchase Option Closing Date shall be the date [ * ]; and (B) if Dynavax
determines that an HSR Filing is required, [ * ] following the date that Dynavax
receives the necessary Government Approvals related to its HSR Filings;
provided, however that Dynavax and Holdings shall make all necessary HSR Filings
within [ * ] following the Purchase Option Exercise Date and shall diligently
pursue the related regulatory process; and provided, further that (1) if there
is no second request from the Federal Trade Commission or the Department of
Justice, as applicable, with respect to Dynavax’s or Holdings’ HSR Filings, then
in no event shall the Purchase Option Closing Date be more than [ * ] following
the Purchase Option Exercise Date, and (2) if there is a second request from the
Federal Trade Commission or the Department of Justice, as applicable, with
respect to Dynavax’s or Holdings’ HSR Filings, then in no event shall the
Purchase Option Closing Date be more than [ * ] days following the Purchase
Option Exercise Date. If Dynavax shall fail to make such cash payment within
such [ * ] day period or [ * ] day period, as applicable, then in addition to
any other rights that Holdings shall have
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

3

--------------------------------------------------------------------------------

 

hereunder, this Agreement shall terminate and Dynavax shall relinquish all
rights hereunder to purchase the Symphony Dynamo Equity Securities; or
     (ii) If Dynavax elects to pay a portion of the Purchase Price in Dynavax
Common Stock (subject to the limitations set forth herein and in the
Registration Rights Agreement), the Purchase Option Closing Date shall be the
date that is the later of:
     (A) [ * ] following the Effective Registration Date of such Dynavax Common
Stock; provided, that Dynavax shall file the Registration Statement contemplated
by Section 3(b)(i) within (x) [ * ] Business Days after the Purchase Option
Exercise Date if Dynavax is eligible to use Form S-3 under the Securities Act
(or any successor form), or (y) [ * ] Business Days after the Purchase Option
Exercise Date if Dynavax is not eligible to use Form S-3 under the Securities
Act (or any successor form); and
     (B) [ * ] following the date that Dynavax receives the necessary Government
Approvals related to its HSR Filings; provided, however, that Dynavax and
Holdings shall make all necessary HSR Filings within [ * ] following the
Purchase Option Exercise Date and shall diligently pursue the related regulatory
process;
provided, further, that Dynavax shall use commercially reasonable efforts to
have such Registration Statement declared effective by the United States
Securities and Exchange Commission as promptly as possible. In the event that
such Registration Statement is not declared effective within [ * ] days of the
Purchase Option Exercise Date, Dynavax shall pay the full Purchase Price in cash
within two (2) Business Days thereafter (in which event the Purchase Option
Closing Date shall be the date upon which such cash payment is made by Dynavax).
If Dynavax shall fail to make such cash payment within such two (2) Business Day
period, then in addition to any other rights that Holdings shall have hereunder,
this Agreement shall terminate and Dynavax shall relinquish all rights hereunder
to purchase the Symphony Dynamo Equity Securities.
          (b) Purchase Price Upon Option Exercise. Upon exercise of the Purchase
Option and as complete and full consideration for the sale to Dynavax by
Holdings of its Symphony Dynamo Equity Securities (and for the Symphony Dynamo
Equity Securities of any other Person), Dynavax shall pay to Holdings the
“Purchase Price”, as follows:
     (i) If the Purchase Option is exercised on or after the Purchase Option
Commencement Date and prior to the date that is the first date [ * ] (the
“Purchase Option Interim Date”), then the Purchase Price shall be an amount
equal to (x) the amount set forth on Schedule I applicable to [ * ] (the
“Quarterly Price”), plus (y) an amount equal to the amount of the [ * ] by [ *
]; provided, that in no event shall the total Purchase Price under this
Section 2(b)(i) exceed [ * ], as set forth on Schedule I hereto; or
     (ii) If the Purchase Option is exercised on or after the Purchase Option
Interim Date, then the Purchase Price shall be an amount equal to the applicable
Quarterly Price; or
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

4

--------------------------------------------------------------------------------

 

     (iii) In the event of an Early Purchase Option Exercise, pursuant to
Section 1(c)(iv) hereof, the Purchase Price shall be an amount equal to the
amount set forth on Schedule I [ * ].
          (c) Form of Payment. Subject to Sections 2(a) and 2(e), the Purchase
Price may be paid in cash or in a combination of cash and Dynavax Common Stock,
at the sole discretion of Dynavax; provided, that in no event may the value of
Dynavax Common Stock (determined in accordance with Section 2(e) hereof)
delivered in connection with the exercise of the Purchase Option constitute more
than either [ * ].
          (d) Surrender of Symphony Dynamo Equity Securities. Subject to the
terms and conditions of this Agreement, on or prior to the Purchase Option
Closing Date, Holdings shall surrender to Dynavax its certificates representing
its Symphony Dynamo Equity Securities, and shall convey good title to such
Symphony Dynamo Equity Securities, free from any Encumbrances and from any and
all restrictions that any sale, assignment or other transfer of such Symphony
Dynamo Equity Securities be consented to or approved by any Person. On or prior
to the Purchase Option Closing Date, Holdings shall remove all directors serving
on the Symphony Dynamo Board, other than the Dynavax Director (as defined in
Section 4(b)(iv) hereof) from the Symphony Dynamo Board as of the Purchase
Option Closing Date.
          (e) Valuation of Dynavax Stock. In the event that Dynavax elects to
pay part of the Purchase Price through the delivery to Holdings of Dynavax
Common Stock, the value per share thereof (the “Dynavax Common Stock Valuation”)
shall equal the average closing price of Dynavax Common Stock, as reported by
the NASDAQ National Market, or other national exchange that is the primary
exchange on which Dynavax Common Stock is listed, for the thirty (30) trading
days immediately preceding the second trading day prior to the Purchase Option
Exercise Date. If Dynavax Common Stock is not traded on a national exchange or
the NASDAQ National Market, then Dynavax shall be obligated to pay the Purchase
Price solely in cash on the Purchase Option Closing Date. Dynavax shall
calculate the Dynavax Common Stock Valuation in accordance with this
Section 2(e), subject to review and confirmation by Holdings.
          (f) Share Certificates. Any stock certificate(s) issued by Dynavax for
Dynavax Common Stock pursuant to this Section 2 may contain a legend (the “33
Act Legend”) substantially as follows:
THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE,
AND THE SAME HAVE BEEN ISSUED IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION
REQUIREMENTS OF SAID ACT AND SUCH LAWS. SUCH SHARES MAY NOT BE SOLD,
TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT AS PERMITTED
UNDER SUCH SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.
This legend shall be removed by Dynavax, subject to, and in accordance with, the
terms of Section 3(b)(iii) hereof.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

5

--------------------------------------------------------------------------------

 

          (g) Government Approvals. On or prior to the Purchase Option Closing
Date, each of Dynavax, Symphony Dynamo and Holdings shall have taken all
necessary action to cause all Governmental Approvals with respect to such Party
(including, if deemed necessary and without limitation, the preparing and filing
of the pre-merger notification and report forms required under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR
Filings”)) required to be in effect in connection with the transactions
contemplated by this Agreement to be in effect; provided, however, that with
respect to Government Approvals required by a Governmental Authority other than
the United States federal government and its various branches and agencies, the
Parties’ obligations under this Section 2(g) shall be limited to causing to be
in effect only those Government Approvals, the failure of which to be in effect
would, either individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect on any of the Parties. Each of Symphony Dynamo and
Dynavax shall pay its own costs associated with taking such action. Symphony
Dynamo shall pay any costs of Holdings associated with obtaining Government
Approvals required in connection with the exercise of the Purchase Option. All
other costs and expenses of Holdings shall be paid by Holdings pursuant to
Section 8(b) hereof, including any costs arising from any error in Holdings’
initial valuation of its investment in Symphony Dynamo.
          (h) Transfer of Title. Transfer of title to Dynavax of all of the
Symphony Dynamo Equity Securities shall be deemed to occur automatically on the
Purchase Option Closing Date, subject to the payment by Dynavax on such date of
the Purchase Price and its performance of its other obligations herein required
to be performed under Sections 2(e) and (g), and under the Registration Rights
Agreement, as applicable, on or prior to the Purchase Option Closing Date to the
reasonable satisfaction of Holdings, and thereafter Symphony Dynamo shall treat
Dynavax as the sole holder of all Symphony Dynamo Equity Securities,
notwithstanding the failure of Holdings to tender certificates representing such
shares to Dynavax in accordance with Section 2(d) hereof. After the Purchase
Option Closing Date, Holdings shall have no rights in connection with such
Symphony Dynamo Equity Securities other than the right to receive the Purchase
Price; provided, however, that nothing in this Section 2(h) shall affect the
survivability of any indemnification provision in this Agreement upon
termination of this Agreement.
          (i) Consents and Authorizations. On or prior to the Purchase Option
Closing Date, Dynavax shall have obtained all consents and authorizations
necessary from stockholders and/or its board of directors for the consummation
of the exercise and closing of the Purchase Option, as may be required under the
organizational documents of Dynavax, any prior stockholders or board resolution,
any stock exchange or similar rules or any applicable law; provided, however,
that with respect to consents or authorizations required by a Governmental
Authority other than the United States federal government and its various
branches and agencies, the Parties’ obligations under this Section 2(i) shall be
limited to obtaining only those consents and authorizations, the failure of
which to be obtained would, either individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect on any of the Parties.
          Section 2A. Put Option.
          (a) Holdings has an exclusive put option (the “Put Option”) for 100%
of the Symphony Dynamo Equity Securities which may be exercised if, [ * ] after
Holdings has delivered written notice thereof to such successor entity.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

6

--------------------------------------------------------------------------------

 

          (b) Holdings may exercise the Put Option only by delivery of written
notice (the “Put Option Exercise Notice”) during the Purchase Option Period. The
Put Option Exercise Notice shall be delivered on a Business Day to the successor
entity to Dynavax, with a copy to Symphony Dynamo, and shall thereafter be
deemed for all purposes under the terms of this Agreement to be a Purchase
Option Exercise Notice by Dynavax (in accordance with the provisions of
Section 2 hereof) as of the date such notice is delivered (such date to be
deemed for all purposes under the terms of this Agreement as the Purchase Option
Exercise Date), and all references to Dynavax and Dynavax Common Stock in
Section 2 shall be deemed references to the successor entity to Dynavax and its
common stock, respectively. The Purchase Price with respect to such an exercise
of the Put Option shall be the Purchase Price otherwise applicable (under
Section 2(b) hereof) to the Purchase Option Closing Date selected by Dynavax
following Dynavax’s receipt of the Put Option Exercise Notice.
          Section 3. Dynavax Representations, Warranties and Covenants.
          (a) As of the date hereof, Dynavax hereby represents and warrants,
and, except to the extent that any of the following representations and
warranties is limited to the date of this Agreement or otherwise limited, on the
Purchase Option Closing Date, shall be deemed to have represented and warranted,
to Holdings and Symphony Dynamo that:
     (i) Organization. Dynavax is a corporation, duly organized, validly
existing and in good standing under the laws of the State of Delaware.
     (ii) Authority and Validity. Dynavax has all requisite corporate power and
authority to execute, deliver and perform its obligations under this Agreement
and to consummate the transactions contemplated hereby. The execution, delivery
and performance by Dynavax of this Agreement and the consummation of the
transactions contemplated hereby have been duly and validly authorized by all
necessary action required on the part of Dynavax, and no other proceedings on
the part of Dynavax are necessary to authorize this Agreement or for Dynavax to
perform its obligations under this Agreement. This Agreement constitutes the
lawful, valid and legally binding obligation of Dynavax, enforceable in
accordance with its terms, except as the same may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the
enforcement of creditors’ rights generally and general equitable principles
regardless of whether such enforceability is considered in a proceeding at law
or in equity.
     (iii) No Violation or Conflict. The execution, delivery and performance of
this Agreement and the transactions contemplated hereby do not (A) violate,
conflict with or result in the breach of any provision of the Organizational
Documents of Dynavax, (B) as of the date of this Agreement, and as of the
Purchase Option Closing Date if Dynavax elects to pay part of the Purchase Price
through the delivery of Dynavax Common Stock (a “Partial Stock Payment”),
conflict with or violate any law or Governmental Order applicable to Dynavax or
any of its assets, properties or businesses, or (C) conflict with, result in any
breach of, constitute a default (or event that with the giving of notice or
lapse of time, or both, would become a default) under, require any consent
under, or give to others any rights of termination, amendment, acceleration,
suspension, revocation or
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

7

--------------------------------------------------------------------------------

 

cancellation of, or result in the creation of any Encumbrance on any of the
assets or properties of Dynavax, pursuant to, any note, bond, mortgage or
indenture, contract, agreement, lease, sublease, license, permit, franchise or
other instrument or arrangement to which Dynavax is a party except, in the case
of clauses (B) and (C), to the extent that such conflicts, breaches, defaults or
other matters would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect on Dynavax.
     (iv) Governmental Consents and Approvals. The execution, delivery and
performance of this Agreement by Dynavax do not, and the consummation of the
transactions contemplated hereby (which transactions shall not include the
exercise of the Purchase Option) do not and will not, require any Governmental
Approval which has not already been obtained, effected or provided, except with
respect to which the failure to so obtain, effect or provide would not,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Dynavax.
     (v) Litigation. As of the date of this Agreement, and as of the Purchase
Option Closing Date if Dynavax elects to make a Partial Stock Payment, there are
no actions by or against Dynavax pending before any Governmental Authority or,
to the knowledge of Dynavax, threatened to be brought by or before any
Governmental Authority, that would, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect on Dynavax. There are no pending
or, to the knowledge of Dynavax, threatened actions, to which Dynavax is a party
(or is threatened to be named as a party) to set aside, restrain, enjoin or
prevent the execution, delivery or performance of this Agreement or the
Operative Documents or the consummation of the transactions contemplated hereby
or thereby by any party hereto or thereto. As of the date of this Agreement, and
as of the Purchase Option Closing Date if Dynavax elects to make a Partial Stock
Payment, Dynavax is not subject to any Governmental Order (nor, to the knowledge
of Dynavax, is there any such Governmental Order threatened to be imposed by any
Governmental Authority) that would, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect on Dynavax.
          (b) Dynavax hereby covenants and agrees with Holdings as follows:
     (i) Immediately prior to the Purchase Option Closing Date, Dynavax shall
have sufficient amounts of cash and, if applicable, authorized but unissued,
freely transferable and nonassessable Dynavax Common Stock available to satisfy
the portion of the Purchase Price to be paid in cash or Dynavax Common Stock
pursuant to Sections 2(b) and 2(c). In the event that Dynavax elects to satisfy
any portion of the Purchase Price in Dynavax Common Stock, (A) Dynavax shall
have not later than the Purchase Option Closing Date, a Registration Statement
declared effective by the Securities and Exchange Commission for the resale of
any such shares of Dynavax Common Stock to be delivered in partial satisfaction
of the Purchase Price, accompanied by evidence reasonably acceptable to Holdings
that such Dynavax Common Stock has been approved for listing on the NASDAQ
national market or such other national market on which the Dynavax Common Stock
is then listed, and (B) Dynavax shall deliver to Holdings on or prior to the
Purchase Option Closing Date, a legal opinion of Cooley Godward LLP (or such
other counsel as Dynavax and Holdings shall mutually agree) on the issuance and
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

8

--------------------------------------------------------------------------------

 

sale of such Dynavax Common Stock, which opinion shall be, in form and substance
reasonably acceptable to Holdings.
     (ii) If Dynavax elects to satisfy any portion of the Purchase Price in
Dynavax Common Stock, Dynavax shall convey good and marketable title to such
Dynavax Common Stock, free from any Encumbrances and any and all other
restrictions that any issuance, sale, assignment or other transfer of such
Dynavax Common Stock be consented to or approved by any Person.
     (iii) If the share certificates representing such Dynavax Common Stock
include the 33 Act Legend (as set forth in Section 2(f) hereof), Dynavax shall,
within two (2) Business Days of receiving a request from Holdings or any
“Investor” (as defined in the Registration Rights Agreement), remove or cause to
be removed the 33 Act Legend from the such share certificates as Holdings or
such Investor shall designate, so long as (x) the Dynavax Common Stock
represented by such share certificates has been transferred to a third party in
compliance with the registration requirements of the Securities Act or an
available exemption therefrom, and (y) Dynavax receives a certification from
Holdings, such Investor or a securities broker designated by Holdings or such
Investor to the effect that the sale of such Dynavax Common Stock was made under
a Registration Statement and accompanied by the delivery of a current
prospectus.
     (iv) Upon the expiration of the Purchase Option or the termination of this
Agreement pursuant to Section 9 hereof, or as soon thereafter as is practical,
Dynavax shall (A) in accordance with Sections 2.7 and 2.8 of the Novated and
Restated Technology License Agreement, deliver to Symphony Dynamo all regulatory
submissions, clinical master files, development plans, consultant inputs,
manufacturing reports and, to the extent requested by Symphony, other materials,
documents, files and other information relating to the Programs and necessary to
enable Symphony Dynamo to continue the development of the Programs (or, where
necessary, copies thereof), and (B) in accordance with and pursuant to
Section 2.12 of the Novated and Restated Technology License Agreement, negotiate
in good faith, and on commercially reasonable terms and conditions, a supply
agreement relating to materials, including compounds and Products, required by
Symphony Dynamo or its partners or transferees for the continued development
(including clinical development), manufacture and commercialization of Products.
     (v) In the event that Dynavax exercises the Purchase Option, then Dynavax
shall maintain the separate corporate existence of Symphony Dynamo for a minimum
of two (2) years following such exercise, unless such maintenance would have a
Material Adverse Effect on Dynavax or any of its Affiliates.
          Section 4. Holdings Representations, Warranties and Covenants.
          (a) As of the date hereof, Holdings hereby represents and warrants,
and, except to the extent that any of the following representations and
warranties is limited to the date of this Agreement or otherwise limited, on the
Purchase Option Closing Date, shall be deemed to have represented and warranted,
to Dynavax and Symphony Dynamo that:
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

9

--------------------------------------------------------------------------------

 

     (i) Organization. Holdings is a limited liability company, duly formed,
validly existing and in good standing under the laws of the State of Delaware.
     (ii) Authority and Validity. Holdings has all requisite limited liability
company power and authority to execute, deliver and perform its obligations
under this Agreement and to consummate the transactions contemplated hereby. The
execution, delivery and performance by Holdings of this Agreement and the
consummation of the transactions contemplated hereby have been duly and validly
authorized by all necessary action required on the part of Holdings, and no
other proceedings on the part of Holdings are necessary to authorize this
Agreement or for Holdings to perform its obligations under this Agreement. This
Agreement constitutes the lawful, valid and legally binding obligation of
Holdings, enforceable in accordance with its terms, except as the same may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting the enforcement of creditors’ rights generally and
general equitable principles regardless of whether such enforceability is
considered in a proceeding at law or in equity.
     (iii) No Violation or Conflict. The execution, delivery and performance of
this Agreement and the transactions contemplated hereby do not (A) violate,
conflict with or result in the breach of any provision of the Organizational
Documents of Holdings, (B) as of the date of this Agreement, conflict with or
violate any law or Governmental Order applicable to Holdings or any of its
assets, properties or businesses, or (C) as of the date of this Agreement,
conflict with, result in any breach of, constitute a default (or event that with
the giving of notice or lapse of time, or both, would become a default) under,
require any consent under, or give to others any rights of termination,
amendment, acceleration, suspension, revocation or cancellation of, or result in
the creation of any Encumbrance on any of the assets or properties of Holdings,
pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease,
sublease, license, permit, franchise or other instrument or arrangement to which
Holdings is a party except, in the case of clauses (B) and (C), to the extent
that such conflicts, breaches, defaults or other matters would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect on
Holdings.
     (iv) Governmental Consents and Approvals. The execution, delivery and
performance of this Agreement by Holdings do not, and the consummation of the
transactions contemplated hereby do not and will not, require any Governmental
Approval which has not already been obtained, effected or provided, except with
respect to which the failure to so obtain, effect or provide would not,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Holdings.
     (v) Litigation. As of the date of this Agreement, there are no actions by
or against Holdings pending before any Governmental Authority or, to the
knowledge of Holdings, threatened to be brought by or before any Governmental
Authority, that would, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect on Holdings. There are no pending or, to the
knowledge of Holdings, threatened actions to which Holdings is a party (or is
threatened to be named as a party) to set aside, restrain, enjoin or prevent the
execution, delivery or performance of this Agreement or
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

10

--------------------------------------------------------------------------------

 

the Operative Documents or the consummation of the transactions contemplated
hereby or thereby by any party hereto or thereto. As of the date of this
Agreement, Holdings is not subject to any Governmental Order (nor, to the
knowledge of Holdings, is there any such Governmental Order threatened to be
imposed by any Governmental Authority) that would, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect on Holdings.
     (vi) Stock Ownership. All of Symphony Dynamo’s issued and outstanding
Symphony Dynamo Equity Securities are owned beneficially and of record by
Holdings, free and clear of any and all encumbrances.
     (vii) Interim Operations. Holdings was formed solely for the purpose of
engaging in the transactions contemplated by the Operative Documents, has
engaged in no other business activities and has conducted its operations only as
contemplated by the Operative Documents.
     (viii) Accredited Investor.
     (A) Holdings is and will remain at all relevant times an Accredited
Investor.
     (B) Holdings has relied completely on the advice of, or has consulted with
or has had the opportunity to consult with, its own personal tax, investment,
legal or other advisors and has not relied on Dynavax or any of its Affiliates
for advice related to any offer and sale of Dynavax Common Stock in connection
with the Purchase Option. Holdings has reviewed the Investment Overview and is
aware of the risks disclosed therein. Holdings acknowledges that it has had a
reasonable opportunity to conduct its own due diligence with respect to the
Products, the Programs, Symphony Dynamo, Dynavax and the transactions
contemplated by the Operative Documents.
     (C) Holdings is able to bear the economic risk of such investment for an
indefinite period and to afford a complete loss thereof
     (D) Holdings agrees that the Dynavax Common Stock may not be resold
(1) without registration thereof under the Securities Act (unless an exemption
from such registration is available), or (2) in violation of any law.
     (E) No person or entity acting on behalf of, or under the authority of,
Holdings is or will be entitled to any broker’s, finder’s, or similar fees or
commission payable by Dynavax or any of its Affiliates.
          (b) Holdings hereby covenants and agrees with Dynavax as follows:
     (i) Contribution to Symphony Dynamo. On or prior to the Stock Payment Date,
Holdings shall, pursuant to the Subscription Agreement, use the Initial Funds
(as defined in the Funding Agreement) to pay to Symphony Dynamo the Stock
Purchase Price (in accordance with, and as defined in, the Subscription
Agreement), in respect of
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

11

--------------------------------------------------------------------------------

 

the 50,000 shares of Common Stock delivered to Holdings by Symphony Dynamo as of
the Closing Date. Additionally, (1) upon the earlier of (x) the date on which
Holdings receives a request for additional funds from Symphony Dynamo, and
(y) February 26, 2007, Holdings shall, promptly (but in no event later than the
fifth (5th) day after the receipt of such request) and in accordance with the
terms of Section 2 of the Funding Agreement, submit to Investors a Funding
Notice; provided, that if Holdings has received a Purchase Option Exercise
Notice, it shall not submit to Investors a Funding Notice, and (2) upon Holdings
receiving any additional net proceeds from any financing received from Investors
in accordance with the Funding Agreement for the purpose of the contribution of
such proceeds to Symphony Dynamo, Holdings shall contribute promptly such
proceeds thereof to Symphony Dynamo.
     (ii) Encumbrance. Holdings will not, and will not permit any of its
Subsidiaries to, create, assume or suffer to exist any Encumbrance on any of its
Symphony Dynamo Equity Securities except with the prior written consent of
Dynavax.
     (iii) Transfer and Amendment. Commencing upon the date hereof and ending
upon the earlier to occur of (x) the Purchase Option Closing Date, (y) the
unexercised expiration of the Purchase Option Period, and (z) the termination of
this Agreement pursuant to Section 9(b) (such period, the “Term”), the manager
of Holdings shall not (A) transfer, or permit the transfer of, any Membership
Interest without the prior written consent of Dynavax or (B) amend, or permit
the amendment of, any provisions relating to the transfer of Membership
Interests, as set forth in Section 7.02 of the Holdings LLC Agreement, to the
extent such amendment would adversely affect Dynavax’s right of consent set
forth in Sections 7.02(b)(i) and 7.02(c) of the Holdings LLC Agreement.
     (iv) Symphony Dynamo Directors. During the Term, Holdings agrees to vote
all of its Symphony Dynamo Equity Securities (or to exercise its right with
respect to such Symphony Dynamo Equity Securities to consent to action in
writing without a meeting) in favor of, as applicable, the election, removal and
replacement of one director of the Symphony Dynamo Board, and any successor
thereto, designated by Dynavax (the “Dynavax Director”) as directed by Dynavax.
In furtherance and not in limitation of the foregoing, Holdings hereby grants to
Dynavax an irrevocable proxy, with respect to all Symphony Dynamo Equity
Securities now owned or hereafter acquired by Holdings, to vote such Symphony
Dynamo Equity Securities or to exercise the right to consent to action in
writing without a meeting with respect to such Symphony Dynamo Equity
Securities, such irrevocable proxy to be exercised solely for the limited
purpose of electing, removing and replacing the Dynavax Director in the event of
the failure or refusal of Holdings to elect, remove or replace such Dynavax
Director, as directed by Dynavax. Additionally, Holdings agrees, during the
Term, to the selection of two (2) independent directors (of the four (4)
directors of Symphony Dynamo not chosen by Holdings at the direction of
Dynavax), and any successors thereto. Such independent directors shall be
selected by mutual agreement of Dynavax and Holdings.
     (v) Symphony Dynamo Board. During the Term, Holdings shall not vote any of
its Symphony Dynamo Equity Securities (or exercise its rights with respect to
such Symphony Dynamo Equity Securities by written consent without a meeting) to
increase
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

12

--------------------------------------------------------------------------------

 

the size of the Symphony Dynamo Board to more than five (5) members without the
prior written consent of Dynavax.
     (vi) Symphony Dynamo Charter. During the Term, Holdings shall not approve
or permit any amendment to Article IV, Paragraphs (1) and (3); Article VI;
Article VII; Article X; Article XI or Article XIII of the Symphony Dynamo
Charter without the prior written consent of Dynavax.
          Section 5. Symphony Dynamo Representations, Warranties and Covenants.
          (a) As of the date hereof, Symphony Dynamo hereby represents and
warrants, and, except to the extent that any of the following representations
and warranties is limited to the date of this Agreement or otherwise limited, on
the Purchase Option Closing Date, shall be deemed to have represented and
warranted, to Dynavax and Holdings that:
     (i) Organization. Symphony Dynamo is a corporation, duly organized, validly
existing and in good standing under the laws of the State of Delaware.
     (ii) Authority and Validity. Symphony Dynamo has all requisite corporate
power and authority to execute, deliver and perform its obligations under this
Agreement and to consummate the transactions contemplated hereby. The execution,
delivery and performance by Symphony Dynamo of this Agreement and the
consummation of the transactions contemplated hereby have been duly and validly
authorized by all necessary action required on the part of Symphony Dynamo, and
no other proceedings on the part of Symphony Dynamo are necessary to authorize
this Agreement or for Symphony Dynamo to perform its obligations under this
Agreement. This Agreement constitutes the lawful, valid and legally binding
obligation of Symphony Dynamo, enforceable in accordance with its terms, except
as the same may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting the enforcement of creditors’ rights
generally and general equitable principles regardless of whether such
enforceability is considered in a proceeding at law or in equity.
     (iii) No Violation or Conflict. The execution, delivery and performance of
this Agreement and the transactions contemplated hereby do not (A) violate,
conflict with or result in the breach of any provision of the Organizational
Documents of Symphony Dynamo, (B) conflict with or violate any law or
Governmental Order applicable to Symphony Dynamo or any of its assets,
properties or businesses, or (C) conflict with, result in any breach of,
constitute a default (or event that with the giving of notice or lapse of time,
or both, would become a default) under, require any consent under, or give to
others any rights of termination, amendment, acceleration, suspension,
revocation or cancellation of, or result in the creation of any Encumbrance on
any of the assets or properties of Symphony Dynamo, pursuant to, any note, bond,
mortgage or indenture, contract, agreement, lease, sublease, license, permit,
franchise or other instrument or arrangement to which Symphony Dynamo is a party
except, in the case of clauses (B) and (C), to the extent that such conflicts,
breaches, defaults or other matters would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Symphony Dynamo.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

13

--------------------------------------------------------------------------------

 

     (iv) Governmental Consents and Approvals. The execution, delivery and
performance of this Agreement by Symphony Dynamo do not, and the consummation of
the transactions contemplated hereby do not and will not, require any
Governmental Approval which has not already been obtained, effected or provided,
except with respect to which the failure to so obtain, effect or provide would
not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Symphony Dynamo.
     (v) Litigation. There are no actions by or against Symphony Dynamo pending
before any Governmental Authority or, to the knowledge of Symphony Dynamo,
threatened to be brought by or before any Governmental Authority that would,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Symphony Dynamo. There are no pending or, to the knowledge of
Symphony Dynamo, threatened actions to which Symphony Dynamo is a party (or is
threatened to be named as a party) to set aside, restrain, enjoin or prevent the
execution, delivery or performance of this Agreement or the Operative Documents
or the consummation of the transactions contemplated hereby or thereby by any
party hereto or thereto. Symphony Dynamo is not subject to any Governmental
Order (nor, to the knowledge of Symphony Dynamo, is there any such Governmental
Order threatened to be imposed by any Governmental Authority) that would,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Symphony Dynamo.
     (vi) Capitalization. Holdings is the beneficial and record owner of all
issued and outstanding Symphony Dynamo Equity Securities. No shares of Symphony
Dynamo capital stock are held in treasury by Symphony Dynamo or any Symphony
Dynamo Subsidiary. All of the issued and outstanding Symphony Dynamo Equity
Securities (A) have been duly authorized and validly issued and are fully paid
and nonassessable, (B) were issued in compliance with all applicable state and
federal securities laws, and (C) were not issued in violation of any preemptive
rights or rights of first refusal. No preemptive rights or rights of first
refusal exist with respect to any Symphony Dynamo Equity Securities and no such
rights will arise by virtue of or in connection with the transactions
contemplated hereby (other than for the Purchase Option). Other than the
Purchase Option, there are no outstanding options, warrants, call rights,
commitments or agreements of any character to acquire any Symphony Dynamo Equity
Securities. There are no outstanding stock appreciation, phantom stock, profit
participation or other similar rights with respect to Symphony Dynamo. Symphony
Dynamo is not obligated to redeem or otherwise acquire any of its outstanding
Symphony Dynamo Equity Securities.
     (vii) Interim Operations. Symphony Dynamo was formed solely for the purpose
of engaging in the transactions contemplated by the Operative Documents, has
engaged in no other business activities and has conducted its operations only as
contemplated by the Operative Documents.
     (viii) Investment Company. Symphony Dynamo is not, and after giving effect
to the transactions contemplated by the Operative Documents will not be,
required to register as an “investment company” as such term is defined in the
Investment Company Act of 1940, as amended.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

14

--------------------------------------------------------------------------------

 

          (b) Symphony Dynamo covenants and agrees that:
     (i) Symphony Dynamo will comply with all laws, ordinances or governmental
rules or regulations to which it is subject and will obtain and maintain in
effect all licenses, certificates, permits, franchises and other Governmental
Approvals necessary to the ownership of its properties or to the conduct of its
business, in each case to the extent necessary to ensure that non-compliance
with such laws, ordinances or governmental rules or regulations or failures to
obtain or maintain in effect such licenses, certificates, permits, franchises
and other Governmental Approvals would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Symphony Dynamo.
     (ii) Symphony Dynamo will file (or cause to be filed) all material tax
returns required to be filed by it and pay all taxes shown to be due and payable
on such returns and all other taxes imposed on it or its assets to the extent
such taxes have become due and payable and before they have become delinquent
and shall pay all claims for which sums have become due and payable that have or
might become attached to the assets of Symphony Dynamo; provided, that Symphony
Dynamo need not file any such tax returns or pay any such tax or claims if
(A) the amount, applicability or validity thereof is contested by Symphony
Dynamo on a timely basis in good faith and in appropriate proceedings, and
Symphony Dynamo has established adequate reserves therefor in accordance with
GAAP on the books of Symphony Dynamo or (B) the failure to file such tax returns
or the nonpayment of such taxes and assessments, individually or in the
aggregate, could not reasonably be expected to have a Material Adverse Effect on
Symphony Dynamo.
     (iii) Symphony Dynamo will at all times preserve and keep in full force and
effect its corporate existence.
     (iv) Symphony Dynamo will keep complete, proper and separate books of
record and account, including a record of all costs and expenses incurred, all
charges made, all credits made and received, and all income derived in
connection with the operation of the business of Symphony Dynamo, all in
accordance with GAAP, in each case to the extent necessary to enable Symphony
Dynamo to comply with the periodic reporting requirements of this Agreement.
     (v) Symphony Dynamo will perform and observe in all material respects all
of the terms and provisions of each Operative Document to be performed or
observed by it, maintain each such Operative Document to which it is a party,
promptly enforce in all material respects each such Operative Document in
accordance with its terms, take all such action to such end as may be from time
to time reasonably requested by Holdings or Dynavax and make to each other party
to each such Operative Document such demands and requests for information and
reports or for action as Symphony Dynamo is entitled to make under such
Operative Document.
     (vi) Symphony Dynamo shall permit the representatives of Holdings
(including Holdings’ members and their respective representatives), each
Symphony
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

15

--------------------------------------------------------------------------------

 

Fund and Dynavax, at each of their own expense and upon reasonable prior notice
to Symphony Dynamo, to visit the principal executive office of Symphony Dynamo,
to discuss the affairs, finances and accounts of Symphony Dynamo with Symphony
Dynamo’s officers and (with the consent of Symphony Dynamo, which consent will
not be unreasonably withheld) the Symphony Dynamo Auditors (as defined in
Section 5(d)(iii) hereof), all at such reasonable times and as often as may be
reasonably requested in writing.
     (vii) Symphony Dynamo shall permit each Symphony Fund, at its own expense
and upon reasonable prior notice to Symphony Dynamo, to inspect and copy
Symphony Dynamo’s books and records and inspect Symphony Dynamo’s properties at
reasonable times.
     (viii) Symphony Dynamo shall allow Dynavax or its designated
representatives to have reasonable visitation and inspection rights with regard
to the Programs and materials, documents and other information relating thereto.
     (ix) Symphony Dynamo shall permit each Symphony Fund to consult with and
advise the management of Symphony Dynamo on matters relating to the research and
development of the Programs in order to develop the Product.
     (x) On the Purchase Option Closing Date, or as soon thereafter as is
practical, Symphony Dynamo shall deliver to Dynavax all materials, documents,
files and other information relating to the Programs (or, where necessary,
copies thereof).
     (xi) During the Term, Dynavax shall have the right to consent to any
increase in the size of the Symphony Dynamo Board to more than five
(5) directors.
     (xii) During the Term, Dynavax shall have the right to designate, remove
and replace one (1) director of the Symphony Dynamo Board and consent to the
selection of the two (2) independent directors (of the four (4) directors of
Symphony Dynamo not chosen by Holdings at the direction of Dynavax), in each
case including any successors thereto and in accordance with the terms of
Section 4(b)(iv).
     (xiii) Symphony Dynamo shall indemnify the directors and officers of
Symphony Dynamo against liability incurred by reason of the fact that such
Person is or was a director or officer of Symphony Dynamo, as permitted by
Article VII of the Symphony Dynamo Charter and Section 9.01 of the Symphony
Dynamo By-laws, as set forth in, and on the terms of, the Indemnification
Agreement and the RRD Services Agreement, respectively.
     (xiv) During the Term, Symphony Dynamo shall comply with, and cause any
Persons acting for it to comply with, the terms of the Investment Policy with
respect to the investment of any funds held by it.
          (c) Symphony Dynamo covenants and agrees that, until the expiration of
the Term, it shall not, and shall cause its Subsidiaries (if any) not to,
without Dynavax’s prior written consent (such consent, in the case of clause (x)
below, not to be unreasonably withheld):
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

16

--------------------------------------------------------------------------------

 

     (i) issue any Symphony Dynamo Equity Securities or any Equity Securities of
any Subsidiary thereof (other than any issuances of Equity Securities by
Symphony Dynamo made in accordance with Section 1(b) hereof to Holdings so long
as Symphony Dynamo is a wholly owned subsidiary of Holdings, or by a Subsidiary
of Symphony Dynamo to Symphony Dynamo or to another wholly owned Subsidiary of
Symphony Dynamo); provided, however, that in any event any such Symphony Dynamo
Equity Securities or Equity Securities of such Subsidiary shall be issued
subject to the Purchase Option;
     (ii) redeem, repurchase or otherwise acquire, directly or indirectly, any
Symphony Dynamo Equity Securities or the Equity Securities of any Subsidiary of
Symphony Dynamo;
     (iii) create, incur, assume or permit to exist any Debt other than any Debt
incurred pursuant to the Operative Documents and the Development Budget
(including payables incurred in the ordinary course of business) (“Excepted
Debt”); provided, however, that the aggregate outstanding principal amount of
all such Excepted Debt for borrowed money shall not exceed [ * ] at any time;
     (iv) declare or pay dividends or other distributions on any Symphony Dynamo
Equity Securities other than any dividend declared from the proceeds of a sale
or license of a discontinued Program to a third party, in respect of which
Symphony Dynamo shall be entitled to pay (subject to the existence of lawfully
available funds) a dividend equal to the net amount (such net amount calculated
as the gross proceeds received less amounts required to be paid in respect of
any and all corporate taxes owed by Symphony Dynamo as a result of the receipt
of such gross amounts) of such amounts received from such third party;
     (v) enter into any transaction of merger or consolidation, or liquidate,
wind up or dissolve itself, or convey, transfer, license, lease or otherwise
dispose of all, or a material portion of, its properties, assets or business;
     (vi) other than in respect of the Programs, engage in the development of
products for any other company or engage or participate in the development of
products or engage in any other material line of business;
     (vii) other than entering into, and performing its obligations under, the
Operative Documents and participating in the Programs, engage in any action that
negates or is inconsistent with any rights of Dynavax set forth herein;
     (viii) other than as contemplated by the RRD Services Agreement and
Section 6.2 of the Amended and Restated Research and Development Agreement,
hire, retain or contract for the services of, any employees until the
termination of such agreements;
     (ix) incur any financial commitments in respect of the development of the
Programs other than those set forth in the Development Plan and the Development
Budget, or those approved by the Development Committee and, if so required by
the
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

17

--------------------------------------------------------------------------------

 

terms of Paragraph 11 of the Development Committee Charter, the Symphony Dynamo
Board in accordance with the Operative Documents;
     (x) other than any transaction contemplated by the Operative Documents,
enter into or engage in any Conflict Transactions without the prior approval of
a majority of the Disinterested Directors of the Symphony Dynamo Board; or
     (xi) waive, alter, modify, amend or supplement in any manner whatsoever any
material terms and conditions of the RRD Services Agreement, the Funding
Agreement, the Subscription Agreement, or Articles 4 and 6 of the Amended and
Restated Research and Development Agreement, except in compliance with the terms
of the Operative Documents.
          (d) Symphony Dynamo covenants and agrees to deliver, cause to be
delivered, and provide access thereto, to each other Party, each Symphony Fund,
and such Auditors as Dynavax may designate, so long as such Auditors shall be
subject to confidentiality requirements at least as stringent as the
Confidentiality Agreement:
     (i) upon request, copies of the then current Development Plan for each
quarter, on or before March 31, June 30, September 30, and December 31 of each
year;
     (ii) upon request, copies of the then current Development Budget for each
quarter, including a report setting forth in reasonable detail the projected
expenditures by Symphony Dynamo pursuant to the Development Budget, on or before
March 31, June 30, September 30, and December 31 of each year;
     (iii) prior to the close of each fiscal year, Symphony Dynamo shall cause
the Manager to seek to obtain from the Symphony Dynamo Auditors the Client
Schedules to be provided to Dynavax’s Auditors in connection with the Symphony
Dynamo Auditors’ audit of Symphony Dynamo. Within [ * ] Business Days after the
close of each fiscal year, Symphony Dynamo (or the Manager acting on its behalf)
will provide Dynavax’s Auditors with the requested Client Schedules. If the
Symphony Dynamo Auditors deliver the Client Schedules after the end of the
fiscal year, Symphony Dynamo (or the Manager acting on its behalf) will provide
the completed Client Schedules to Dynavax’s Auditors within [ * ] Business Days
of such receipt;
     (iv) prior to the close of each fiscal year, Dynavax’ Vice President of
Finance, the Symphony Dynamo Auditors, Dynavax’s Auditors and Symphony Dynamo
(or the Manager acting on its behalf) shall agree to a completion schedule that
will include (A) the provision by Symphony Dynamo to Dynavax of the financial
information reasonably necessary for Dynavax to consolidate and audit the
financial results of Symphony Dynamo and (B) the following financial statements,
including the related notes thereto, audited and certified by the Symphony
Dynamo Auditors: (1) a balance sheet of Symphony Dynamo as of the close of such
fiscal year, (2) a statement of net income for such fiscal year, and (3) a
statement of cash flows for such fiscal year. Such audited annual financial
statements shall set forth in comparative form the figures for the previous
fiscal year, all in reasonable detail, prepared in accordance with GAAP, and
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

18

--------------------------------------------------------------------------------

 

Symphony Dynamo (or the Manager acting on its behalf) shall, to the extent that
Symphony Dynamo (or the Manager acting on its behalf), using commercially
reasonable means, can procure such an opinion, be accompanied by an opinion
thereon of the Symphony Dynamo Auditors to the effect that such financial
statements present fairly, in all material respects, the financial position of
Symphony Dynamo and its results of operations and cash flows and have been
prepared in conformity with GAAP, and that the examination of such accountants
in connection with such financial statements has been made in accordance with
generally accepted auditing standards, and that such audit provides a reasonable
basis for such opinion in the circumstances;
     (v) within [ * ] Business Days following each calendar month and upon
receipt from Dynavax of its monthly invoice to Symphony Dynamo, current accrued
monthly vendor expenses and prepaid expenses: (A) the unaudited balance sheet of
Symphony Dynamo for the previous calendar month; (B) the unaudited statement of
net income for such previous calendar month; (C) the unaudited statement of cash
flows for such previous calendar month; (D) the trial balance schedule for such
previous calendar month; and (E) related account reconciliations for such
previous calendar month;
     (vi) any other documents, materials or other information, including
information and documentation of internal controls and reporting as may be
required by applicable law, rule or regulation (including information prepared
in support of Symphony Dynamo’s efforts pursuant to Section 5(e)) pertaining to
Holdings, the Programs or Symphony Dynamo as Dynavax may reasonably request,
including preliminary financial information;
     (vii) within [ * ] Business Days following its receipt thereof from
Symphony Dynamo’s tax return preparer, a copy of each income tax return to be
filed by Symphony Dynamo with any foreign, federal, state or local taxing
authority (including all supporting schedules thereto);
     (viii) promptly, and in any event within [ * ] Business Days of receipt
thereof, copies of any notice to Symphony Dynamo from any federal or state
Governmental Authority relating to any order, ruling, statute or other law or
regulation that would reasonably be expected to have a Material Adverse Effect
on Symphony Dynamo;
     (ix) promptly upon receipt thereof, notice of all actions, suits,
investigations, litigation and proceedings before any court or governmental
department, commission, board, bureau, agency or instrumentality, domestic or
foreign, affecting Symphony Dynamo;
     (x) promptly upon receipt thereof, copies of any other notices, requests,
reports, financial statements and other information and documents received by
Symphony Dynamo under or pursuant to any other Operative Document, including,
without limitation, any notices of breach or termination of any subcontracts or
licenses entered into or permitted pursuant to the Operative Documents; and
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

19

--------------------------------------------------------------------------------

 

     (xi) with reasonable promptness, such other data and information relating
to the business, operations, affairs, financial condition, assets or properties
of Symphony Dynamo or relating to the ability of Symphony Dynamo to perform its
obligations hereunder and under the Operative Documents as from time to time may
be reasonably requested by Dynavax and/or Holdings;
provided, that neither Symphony Dynamo, nor the Manager acting on behalf of
Symphony Dynamo, shall have any liability to Dynavax for the failure to deliver
financial documents or other materials hereunder, if such failure was caused by
a failure of Dynavax to provide, in a timely manner, data required to prepare
such financial documents or other materials to Symphony Dynavax in a timely
manner.
          (e) Symphony Dynamo will use commercially reasonable efforts, at its
own expense (as set forth in the Management Budget), to cooperate with Dynavax
in meeting Dynavax’s government compliance, disclosure, and financial reporting
obligations, including without limitation under the Sarbanes-Oxley Act of 2002
and any rules and regulations promulgated thereunder, and under FASB
Interpretation No. 46. Without limiting the foregoing, Symphony Dynamo further
covenants, until the expiration of the Term, that (w) the principal executive
officer and the principal financial officer of Symphony Dynamo, or persons
performing similar functions, shall provide certifications to Dynavax
corresponding to those required with respect to public companies for which a
class of securities is registered under the Exchange Act (“Public Companies”)
under Sections 302 and 906 of the Sarbanes-Oxley Act of 2002; (x) Symphony
Dynamo shall maintain a system of disclosure controls and internal controls (as
defined under the Exchange Act) and conduct quarterly and annual evaluations of
the effectiveness of such controls as required under the Exchange Act for Public
Companies; (y) Symphony Dynamo shall provide to Dynavax an attestation report of
the Symphony Dynamo Auditors with respect to Symphony Dynamo management’s
assessment of Symphony Dynamo’s internal controls as required under the Exchange
Act for Public Companies; and (z) Symphony Dynamo will maintain, or cause to
have maintained, such sufficient evidentiary support for management’s assessment
of the effectiveness of Symphony Dynamo’s internal controls as required for
Public Companies.
          (f) Dynavax agrees to provide reasonable assistance and support for
the financial operations of Symphony Dynamo as may be reasonably requested by
Symphony Dynamo from time to time during the Term; provided that any such
services shall be pursuant to a separate agreement specifying the nature and
amount of assistance and support to be provided and the reimbursement to Dynavax
of costs plus a reasonable profit in the provision of such assistance and
support.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

20

--------------------------------------------------------------------------------

 

          Section 6. Notice of Material Event. Each Party agrees that, upon it
receiving knowledge of a material event or development with respect to any of
the transactions contemplated hereby that, to the knowledge of its executive
officers, is not known to the other Parties, such Party shall notify the other
Parties in writing within three (3) Business Days of the receipt of such
knowledge by any executive officer of such Party; provided, that the failure to
provide such notice shall not impair or otherwise be deemed a waiver of any
rights any Party may have arising from such material event or development and
that notice under this Section 6 shall not in itself constitute notice of any
breach of any of the Operative Documents.
          Section 7. Assignment; Transfers; Legend.
          (a) Assignment by Dynavax and Symphony Dynamo. Neither Dynavax nor
Symphony Dynamo may assign, delegate, transfer, sell or otherwise dispose of
(collectively, “Transfer”), in whole or in part, any or all of their rights or
obligations hereunder to any Person (a “Transferee”) without the prior written
approval of each of the other Parties; provided, however, that Dynavax, without
the prior approval of each of the other Parties, acting in accordance with
Article 14 of the Amended and Restated Research and Development Agreement, may
make such Transfer to any Person which acquires all or substantially all of
Dynavax’s assets or business (or assets or business related to the Programs) or
which is the surviving or resulting Person in a merger or consolidation with
Dynavax; provided, further, that in the event of any Transfer, Dynavax or
Symphony Dynamo, as applicable, shall provide written notice to the other
Parties of any such Transfer not later than thirty (30) days after such Transfer
setting forth the identity and address of the Transferee and summarizing the
terms of the Transfer. In no event shall such assignment alter the definition of
“Dynavax Common Stock” except as a result of the surviving or resulting “parent”
entity in a merger being other than Dynavax, in which case any reference to
Dynavax Common Stock shall be deemed to instead reference the common stock, if
any, of the surviving or resulting entity.
          (b) Assignment and Transfers by Holdings. Prior to the expiration of
the Purchase Option, Holdings may not Transfer, in whole or in part, any or all
of its Symphony Dynamo Equity Securities or any or all of its rights or
obligations hereunder to any Person (other than Dynavax) without the prior
written consent of Dynavax. In addition, any Transfer of Symphony Dynamo Equity
Securities by Holdings or any other Person to any Person other than Dynavax
shall be conditioned upon, and no effect shall be given to any such Transfer
unless such transferee shall agree in writing in form and substance satisfactory
to Dynavax to be bound by all of the terms and conditions hereunder, including
the Purchase Option, as if such transferee were originally designated as
“Holdings” hereunder.
          (c) Legend. Any certificates evidencing Symphony Dynamo Equity
Securities shall bear a legend in substantially the following form:
THE SECURITIES OF SYMPHONY DYNAMO, INC., EVIDENCED HEREBY ARE SUBJECT TO AN
OPTION, HELD BY DYNAVAX, AS DESCRIBED IN A PURCHASE OPTION AGREEMENT (THE
“PURCHASE OPTION AGREEMENT”) DATED AS OF APRIL 18, 2006, BY AND AMONG DYNAVAX
TECHNOLOGIES CORPORATION, AND THE OTHER PARTIES THERETO, TO PURCHASE SUCH
SECURITIES AT A
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

21

--------------------------------------------------------------------------------

 

PURCHASE PRICE DETERMINED PURSUANT TO SECTION 2 OF THE PURCHASE OPTION
AGREEMENT, EXERCISABLE BY WRITTEN NOTICE AT ANY TIME DURING THE PERIOD SET FORTH
THEREIN. COPIES OF THE PURCHASE OPTION AGREEMENT ARE AVAILABLE AT THE PRINCIPAL
PLACE OF BUSINESS OF SYMPHONY DYNAMO, INC. AT 7361 CALHOUN PLACE, SUITE 325,
ROCKVILLE, MARYLAND 20855, AND WILL BE FURNISHED TO THE HOLDER HEREOF UPON
WRITTEN REQUEST WITHOUT COST.
          Section 8. Costs and Expenses; Payments.
          (a) Symphony Dynamo Costs and Expenses. Symphony Dynamo shall pay any
of its ongoing legal expenses with respect to the transactions described in the
Operative Documents from the funds allocated for such purpose in the Management
Budget.
          (b) Costs and Expenses of the Purchase Option. Except as otherwise
specified in Section 2(g) hereof, each Party shall pay its own costs and
expenses incurred in connection with the exercise of the Purchase Option.
          (c) Payments to Holdings. Payment of the Purchase Price, plus any
costs and expenses payable by Symphony Dynamo under Section 2(g) hereof, shall
be made to the account of Holdings contemporaneously with or prior to the payout
of the Purchase Price on the Purchase Option Closing Date no later than 1:00 pm
(New York time).
          Section 9. Expiration; Termination of Agreement
          (a) Unexercised Expiration or Termination. If the Purchase Option
granted hereunder shall terminate or expire unexercised, and the Program Option
shall have previously been exercised, then Dynavax shall make a cash payment to
Holdings in an amount equal to [ * ] in accordance with Section 11.1(c) of the
Amended and Restated Research Agreement.
          (b) Termination.
     (i) This Agreement shall terminate upon the mutual written consent of all
of the Parties.
     (ii) Subject to Section 1(c)(iv) hereof, each of Holdings and Symphony
Dynamo may terminate this Agreement in the event that Symphony Dynamo terminates
the Amended and Restated Research and Development Agreement in accordance with
its terms.
          Section 10. Survival; Indemnification.
          (a) Survival of Representations and Warranties; Expiration of Certain
Covenants.
     (i) The representations and warranties of the Parties contained in this
Agreement shall survive for a period of one year from the making of such
representations. The liability of the Parties related to their respective
representations and
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

22

--------------------------------------------------------------------------------

 

warranties hereunder shall not be reduced by any investigation made at any time
by or on behalf of Holdings, Symphony Dynamo or Dynavax, as applicable.
     (ii) For the avoidance of doubt, the covenants and agreements set forth in
Sections 4(b), 5(b)(i), 5(b)(v)-(ix), 5(b)(xi)-(xiv), 5(c), 5(d)(i), 5(d)(ii)
and 5(d)(viii)-(xi) shall, upon the expiration of the Term, expire and end
without any further obligation by Symphony Dynamo or Holdings thereunder.
     (iii) For the avoidance of doubt, the covenants and agreements set forth in
Sections 5(b)(ii)-(iii), 5(b)(x), 5(d)(iii)-(v), 5(d)(vii), and 5(e) shall, upon
the completion of all the reporting, accounting and other obligations set forth
therein with respect to the fiscal year in which this Agreement shall terminate,
expire and end without any further obligation by Symphony Dynamo or Holdings
thereunder.
          (b) Indemnification. To the greatest extent permitted by applicable
law, Dynavax shall indemnify and hold harmless Holdings and Symphony Dynamo and
Holdings shall indemnify and hold harmless Dynavax, and each of their respective
Affiliates, officers, directors, employees, agents, partners, members,
successors, assigns, representatives of, and each Person, if any (including any
officers, directors, employees, agents, partners, members of such Person) who
controls Holdings, Symphony Dynamo and Dynavax, as applicable, within the
meaning of the Securities Act or the Exchange Act, (each, an “Indemnified
Party”), from and against any and all actions, causes of action, suits, claims,
losses, costs, interest, penalties, fees, liabilities and damages, and expenses
in connection therewith (irrespective of whether any such Indemnified Party is a
party to the action for which indemnification hereunder is sought), and
including reasonable attorneys’ fees and disbursements (hereinafter, a “Loss”),
incurred by any Indemnified Party as a result of, or arising out of, or relating
to: (i) in the case of Dynavax being the Indemnifying Party, (A) any breach of
any representation or warranty made by Dynavax herein or in any certificate,
instrument or document delivered in connection and contemporaneously herewith,
or (B) any breach of any covenant, agreement or obligation of Dynavax contained
herein or in any certificate, instrument or document delivered hereunder, and
(ii) in the case of Holdings being the Indemnifying Party, (A) any breach of any
representation or warranty made by Holdings or Symphony Dynamo herein or in any
certificate, instrument or document delivered in connection and
contemporaneously herewith, or (B) any breach of any covenant, agreement or
obligation of Holdings or Symphony Dynamo contained herein or in any
certificate, instrument or document delivered hereunder. To the extent that the
foregoing undertaking by Dynavax or Holdings may be unenforceable for any
reason, such Party shall make the maximum contribution to the payment and
satisfaction of any Loss that is permissible under applicable law.
          (c) Notice of Claims. Any Indemnified Party that proposes to assert a
right to be indemnified under this Section 10 shall notify Dynavax or Holdings,
as applicable (the “Indemnifying Party”), promptly after receipt of notice of
commencement of any action, suit or proceeding against such Indemnified Party
(an “Indemnified Proceeding”) in respect of which a claim is to be made under
this Section 10, or the incurrence or realization of any Loss in respect of
which a claim is to be made under this Section 10, of the commencement of such
Indemnified Proceeding or of such incurrence or realization, enclosing a copy of
all relevant documents, including all papers served and claims made, but the
omission to so notify the applicable
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

23

--------------------------------------------------------------------------------

 

Indemnifying Party promptly of any such Indemnified Proceeding or incurrence or
realization shall not relieve (x) such Indemnifying Party from any liability
that it may have to such Indemnified Party under this Section 10 or otherwise,
except, as to such Indemnifying Party’s liability under this Section 10, to the
extent, but only to the extent, that such Indemnifying Party shall have been
prejudiced by such omission, or (y) any other indemnitor from liability that it
may have to any Indemnified Party under the Operative Documents.
          (d) Defense of Proceedings. In case any Indemnified Proceeding shall
be brought against any Indemnified Party, it shall notify the applicable
Indemnifying Party of the commencement thereof as provided in Section 10(c), and
such Indemnifying Party shall be entitled to participate in, and provided such
Indemnified Proceeding involves a claim solely for money damages and does not
seek an injunction or other equitable relief against the Indemnified Party and
is not a criminal or regulatory action, to assume the defense of, such
Indemnified Proceeding with counsel reasonably satisfactory to such Indemnified
Party. After notice from such Indemnifying Party to such Indemnified Party of
such Indemnifying Party’s election so to assume the defense thereof and the
failure by such Indemnified Party to object to such counsel within ten (10)
Business Days following its receipt of such notice, such Indemnifying Party
shall not be liable to such Indemnified Party for legal or other expenses
related to such Indemnified Proceedings incurred after such notice of election
to assume such defense except as provided below and except for the reasonable
costs of investigating, monitoring or cooperating in such defense subsequently
incurred by such Indemnified Party reasonably necessary in connection with the
defense thereof. Such Indemnified Party shall have the right to employ its
counsel in any such Indemnified Proceeding, but the reasonable fees and expenses
of such counsel shall be at the expense of such Indemnified Party unless:
     (i) the employment of counsel by such Indemnified Party at the expense of
the applicable Indemnifying Party has been authorized in writing by such
Indemnifying Party;
     (ii) such Indemnified Party shall have reasonably concluded in its good
faith (which conclusion shall be determinative unless a court determines that
such conclusion was not reached reasonably and in good faith) that there is or
may be a conflict of interest between the applicable Indemnifying Party and such
Indemnified Party in the conduct of the defense of such Indemnified Proceeding
or that there are or may be one or more different or additional defenses,
claims, counterclaims, or causes of action available to such Indemnified Party
(it being agreed that in any case referred to in this clause (ii) such
Indemnifying Party shall not have the right to direct the defense of such
Indemnified Proceeding on behalf of the Indemnified Party);
     (iii) the applicable Indemnifying Party shall not have employed counsel
reasonably acceptable to the Indemnified Party, to assume the defense of such
Indemnified Proceeding within a reasonable time after notice of the commencement
thereof (provided, however, that this clause (iii) shall not be deemed to
constitute a waiver of any conflict of interest that may arise with respect to
any such counsel); or
     (iv) any counsel employed by the applicable Indemnifying Party shall fail
to timely commence or diligently conduct the defense of such Indemnified
Proceeding and
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

24

--------------------------------------------------------------------------------

 

such failure has materially prejudiced (or, in the reasonable judgment of the
Indemnified Party, is in danger of materially prejudicing) the outcome of such
Indemnified Proceeding;
in each of which cases the reasonable fees and expenses of counsel for such
Indemnified Party shall be at the expense of such Indemnifying Party. Only one
counsel shall be retained by all Indemnified Parties with respect to any
Indemnified Proceeding, unless counsel for any Indemnified Party reasonably
concludes in good faith (which conclusion shall be determinative unless a court
determines that such conclusion was not reached reasonably and in good faith)
that there is or may be a conflict of interest between such Indemnified Party
and one or more other Indemnified Parties in the conduct of the defense of such
Indemnified Proceeding or that there are or may be one or more different or
additional defenses, claims, counterclaims, or causes or action available to
such Indemnified Party.
          (e) Settlement. Without the prior written consent of such Indemnified
Party, such Indemnifying Party shall not settle or compromise, or consent to the
entry of any judgment in, any pending or threatened Indemnified Proceeding,
unless such settlement, compromise, consent or related judgment (i) includes an
unconditional release of such Indemnified Party from all liability for Losses
arising out of such claim, action, investigation, suit or other legal
proceeding, (ii) provides for the payment of money damages as the sole relief
for the claimant (whether at law or in equity), (iii) involves no finding or
admission of any violation of law or the rights of any Person by the Indemnified
Party, and (iv) is not in the nature of a criminal or regulatory action. No
Indemnified Party shall settle or compromise, or consent to the entry of any
judgment in, any pending or threatened Indemnified Proceeding in respect of
which any payment would result hereunder or under the Operative Documents
without the prior written consent of the Indemnifying Party, such consent not to
be unreasonably conditioned, withheld or delayed.
          Section 11. No Petition. Each of Dynavax and Holdings covenants and
agrees that, prior to the date which is one year and one day after the
expiration of the Purchase Option Period, it will not institute or join in the
institution of any bankruptcy, insolvency, reorganization or similar proceeding
against Symphony Dynamo. The provisions of this Section 11 shall survive the
termination of this Agreement.
          Section 12. Third-Party Beneficiary. Each of the Parties agrees that
each Symphony Fund shall be a third-party beneficiary of this Agreement.
          Section 13. Notices. Any notice, request, demand, waiver, consent,
approval or other communication which is required or permitted to be given to
any Party shall be in writing and shall be deemed given only if delivered to the
Party personally or sent to the Party by facsimile transmission (promptly
followed by a hard-copy delivered in accordance with this Section 13), by next
Business Day delivery by a nationally recognized courier service, or by
registered or certified mail (return receipt requested), with postage and
registration or certification fees thereon prepaid, addressed to the Party at
its address set forth below:
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

25

--------------------------------------------------------------------------------

 

Dynavax:
Dynavax Technologies Corporation
2929 Seventh Street, Suite 100
Berkeley, CA 94710
Attn: Deborah Smeltzer, VP, Operations & CFO
Facsimile: (510) 848-1327
Symphony Dynamo:
Symphony Dynamo, Inc.
7361 Calhoun Place, Suite 325
Rockville, MD 20850
Attn: Charles W. Finn, Ph.D.
Facsimile: (301) 762-6154
Holdings:
Symphony Dynamo Holdings LLC
7361 Calhoun Place, Suite 325
Rockville, MD 20850
Attn: Joseph P. Clancy
Facsimile: (301) 762-6154
   with copies to:
Symphony Capital Partners, L.P.
875 Third Avenue
18th Floor
New York, NY 10022
Attn: Mark Kessel
Facsimile: (212) 632-5401
   and
Symphony Strategic Partners, LLC
875 Third Avenue
18th Floor
New York, NY 10022
Attn: Mark Kessel
Facsimile: (212) 632-5401
or to such other address as such Party may from time to time specify by notice
given in the manner provided herein to each other Party entitled to receive
notice hereunder.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

26

--------------------------------------------------------------------------------

 

          Section 14. Governing Law; Consent to Jurisdiction and Service of
Process.
          (a) This Agreement shall be governed by, and construed in accordance
with, the laws of the State of New York; except to the extent that this
Agreement pertains to the internal governance of Symphony Dynamo or Holdings,
and to such extent this Agreement shall be governed and construed in accordance
with the laws of the State of Delaware.
          (b) Each of the Parties hereby irrevocably and unconditionally
submits, for itself and its property, to the nonexclusive jurisdiction of any
New York State court and Delaware State court or federal court of the United
States of America sitting in The City of New York, Borough of Manhattan or
Wilmington, Delaware, and any appellate court from any jurisdiction thereof, in
any action or proceeding arising out of or relating to this Agreement, or for
recognition or enforcement of any judgment, and each of the Parties hereby
irrevocably and unconditionally agrees that all claims in respect of any such
action or proceeding may be heard and determined in any such New York State
court, any such Delaware State court or, to the fullest extent permitted by law,
in such federal court. Each of the Parties agrees that a final judgment in any
such action or proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by law.
Nothing in this Agreement shall affect any right that any Party may otherwise
have to bring any action or proceeding relating to this Agreement.
          (c) Each of the Parties irrevocably and unconditionally waives, to the
fullest extent it may legally and effectively do so, any objection that it may
now or hereafter have to the laying of venue of any suit, action or proceeding
arising out of or relating to this Agreement in any New York State or federal
court, or any Delaware State or federal court. Each of the Parties hereby
irrevocably waives, to the fullest extent permitted by law, the defense of an
inconvenient forum to the maintenance of such action or proceeding in any such
court. Each of the parties hereby consents to service of process by mail.
          SECTION 15. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO
IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR
COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR
RELATING TO THIS AGREEMENT.
          Section 16. Entire Agreement. This Agreement (including any Annexes,
Schedules, Exhibits or other attachments hereto) constitutes the entire
agreement between the Parties with respect to the matters covered hereby and
supersedes all prior agreements and understanding with respect to such matters
between the Parties.
          Section 17. Amendment; Successors; Counterparts.
          (a) The terms of this Agreement shall not be altered, modified,
amended, waived or supplemented in any manner whatsoever except by a written
instrument signed by each of the Parties.
          (b) Except as set forth in Section 12, nothing expressed or implied
herein is intended or shall be construed to confer upon or to give to any
Person, other than the Parties, any
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

27

--------------------------------------------------------------------------------

 

right, remedy or claim under or by reason of this Agreement or of any term,
covenant or condition hereof, and all the terms, covenants, conditions, promises
and agreements contained herein shall be for the sole and exclusive benefit of
the Parties and their successors and permitted assigns.
          (c) This Agreement may be executed in one or more counterparts, each
of which, when executed, shall be deemed an original but all of which, taken
together, shall constitute one and the same Agreement.
          Section 18. Specific Performance. The Parties acknowledge that
irreparable damage would result if this Agreement were not specifically
enforced, and they therefore agree that the rights and obligations of the
Parties under this Agreement may be enforced by a decree of specific performance
issued by a court of competent jurisdiction. Such a remedy shall, however, not
be exclusive, and shall be in addition to any other remedies which any Party may
have under this Agreement or otherwise. The Parties further acknowledge and
agree that a decree of specific performance may not be an available remedy in
all circumstances.
          Section 19. Severability. If any term or other provision of this
Agreement is invalid, illegal or incapable of being enforced by any rule of law
or public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect so long as the economic or legal
substance of the transactions contemplated hereby is not affected in a manner
materially adverse to either party. Upon such determination that any term or
other provision is invalid, illegal or incapable of being enforced, the parties
hereto shall negotiate in good faith to modify this Agreement so as to effect
the original intent of the parties as closely as possible in an acceptable
manner to the end that the transactions contemplated hereby are fulfilled to the
extent possible.
          Section 20. Tax Reporting . The Parties acknowledge and agree that,
for all federal and state income tax purposes:
          (a) (i) Holdings shall be treated as the owner of all the Equity
Securities of Symphony Dynamo; (ii) the Purchase Option shall be treated as an
option to acquire all the Equity Securities of Symphony Dynamo; (iii) the
Warrant shall be treated as option premium payable in respect of the grant of
the Purchase Option; and (iv) Symphony Dynamo shall be treated as the owner of
all the Licensed Intellectual Property and shall be entitled to all deductions
claimed under Section 174 of the Code in respect of the Licensed Intellectual
Property to the extent of the amounts funded by Symphony Dynamo; and
          (b) no Party shall take any tax position inconsistent with any
position described in Section 20(a) above, except (i) in the event of a
“determination” (as defined in Section 1313 of the Code) to the contrary, or
(ii) in the event either of the Parties receives an opinion of counsel to the
effect that there is no reasonable basis in law for such a position or that a
tax return cannot be prepared based on such a position without being subject to
substantial understatement penalties; provided, however, that in the case of
Dynavax, such counsel shall be reasonably satisfactory to Holdings.
{SIGNATURES FOLLOW ON NEXT PAGE}
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

28

--------------------------------------------------------------------------------

 

          IN WITNESS WHEREOF, the parties hereto have signed this Agreement as
of the day and year first above written.

            DYNAVAX TECHNOLOGIES CORPORATION
      By:   /s/ Dino Dina         Name:   Dino Dina, M.D.        Title:  
President & Chief Executive Officer        SYMPHONY DYNAMO HOLDINGS LLC
      By:   Symphony Capital Partners, L.P.,         its Manager           
By:   Symphony Capital GP, L.P.,         its general partner            By:  
Symphony GP, LLC,         its general partner            By:   /s/ Mark Kessel  
      Name:   Mark Kessel        Title:   Managing Member        SYMPHONY
DYNAMO, INC.
      By:   /s/ Harri V. Taranto         Name:   Harri V. Taranto       
Title:   Chairman of the Board     

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
Purchase Option Agreement

 

--------------------------------------------------------------------------------

 

SCHEDULE I
PURCHASE PRICE TABLE
[ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

ANNEX A
CERTAIN DEFINITIONS
          “$” means United States dollars.
          “Accredited Investor” has the meaning set forth in Rule 501(a) of
Regulation D promulgated under the Securities Act of 1933, as amended.
          “Act” means the Delaware Limited Liability Company Act, 6 Del. C. §
18-101 et seq.
          “Ad Hoc Meeting” has the meaning set forth in Paragraph 6 of Annex B
of the Amended and Restated Research and Development Agreement.
          “Additional Funds” has the meaning set forth in Section 2(b) of the
Funding Agreement.
          “Additional Funding Date” has the meaning set forth in Section 3 of
the Funding Agreement.
          “Additional Party” has the meaning set forth in Section 13 of the
Confidentiality Agreement.
          “Additional Regulatory Filings” means such Governmental Approvals as
required to be made under any law applicable to the purchase of the Symphony
Dynamo Equity Securities under the Purchase Option Agreement.
          “Adjusted Capital Account Deficit” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement.
          “Affected Member” has the meaning set forth in Section 27 of the
Investors LLC Agreement.
          “Affiliate” means, with respect to any Person (i) any Person directly
or indirectly controlling, controlled by or under common control with such
Person, (ii) any officer, director, general partner, member or trustee of such
Person, or (iii) any Person who is an officer, director, general partner, member
or trustee of any Person described in clauses (i) or (ii) of this sentence. For
purposes of this definition, the terms “controlling,” “controlled by” or “under
common control with” shall mean the possession, direct or indirect, of the power
to direct or cause the direction of the management and policies of a Person or
entity, whether through the ownership of voting securities, by contract or
otherwise, or the power to elect at least 50% of the directors, managers,
general partners, or persons exercising similar authority with respect to such
Person or entities.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Amended and Restated Research and Development Agreement” means the
Amended and Restated Research and Development Agreement dated as of the Closing
Date, among Dynavax, Holdings and Symphony Dynamo.
          “Asset Value” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.
          “Auditors” means an independent certified public accounting firm of
recognized national standing.
          [ * ]
          “Bankruptcy Code” means the United States Bankruptcy Code.
          “Berna” has the meaning set forth in Section 11.1(a) of the Amended
and Restated Research and Development Agreement.
          “Business Day” means any day other than Saturday, Sunday or any other
day on which commercial banks in The City of New York or the City of San
Francisco are authorized or required by law to remain closed.
          “Cancer Products” mean [ * ].
          “Cancer Program” means the identification, development, manufacture
and/or use of any Cancer Products in accordance with the Development Plan.
          “Capital Contributions” has the meaning set forth in Section 1.01 of
the Holdings LLC Agreement.
          “Capitalized Leases” means all leases that have been or should be, in
accordance with GAAP, recorded as capitalized leases.
          “Cash Available for Distribution” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement.
          “Chair” has the meaning set forth in Paragraph 4 of Annex B to the
Amended and Restated Research and Development Agreement.
          “Change of Control” means and includes the occurrence of any of the
following events, but specifically excludes (i) acquisitions of capital stock
directly from Dynavax for cash, whether in a public or private offering,
(ii) sales of capital stock by stockholders of Dynavax, and (iii) acquisitions
of capital stock by or from any employee benefit plan or related trust:
     (a) the merger, reorganization or consolidation of Dynavax into or with
another corporation or legal entity in which Dynavax’s stockholders holding the
right to vote with respect to matters generally immediately preceding such
merger, reorganization or consolidation, own less than fifty percent (50%) of
the voting securities of the surviving entity; or
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

     (b) the sale of all or substantially all of Dynavax’s assets or business.
          “Class A Member” means a holder of a Class A Membership Interest.
          “Class A Membership Interest” means a Class A Membership Interest in
Holdings.
          “Class B Member” means a holder of a Class B Membership Interest.
          “Class B Membership Interest” means a Class B Membership Interest in
Holdings.
          “Class C Member” means a holder of a Class C Membership Interest.
          “Class C Membership Interest” means a Class C Membership Interest in
Holdings.
          “Closing Certificate for Section 5.1(e)” means the written
certificate, pertaining to the representations made by Dynavax under
Section 5.1(e) of the Novated and Restated Technology License Agreement,
provided by Dynavax to Symphony Dynamo Holdings LLC and Symphony Dynamo on the
Closing Date.
          “Closing Certificate for Section 5.1(f)” means the written
certificate, pertaining to the representations made by Dynavax under
Section 5.1(f) of the Novated and Restated Technology License Agreement,
provided by Dynavax to Symphony Dynamo Holdings LLC and Symphony Dynamo on the
Closing Date.
          “Client Schedules” has the meaning set forth in Section 5(b)(i) of the
RRD Services Agreement.
          “Clinical Budget Component” has the meaning set forth in Section 4.1
of the Amended and Restated Research and Development Agreement.
          “Closing Date” means April 18, 2006.
          “CMC” means the chemistry, manufacturing and controls documentation as
required for filings with Regulatory Authority relating to the manufacturing,
production and testing of drug products.
          “Code” means the Internal Revenue Code of 1986, as amended from time
to time.
          “Committed Capital” means $50,000,000.00.
          “Common Stock” means the common stock, par value $0.01 per share, of
Symphony Dynamo.
          “Company Expenses” has the meaning set forth in Section 5.09 of the
Holdings LLC Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Company Property” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.
          “Confidential Information” has the meaning set forth in Section 2 of
the Confidentiality Agreement.
          “Confidentiality Agreement” means the Confidentiality Agreement, dated
as of the Closing Date, among Symphony Dynamo, Holdings, Dynavax, each Symphony
Fund, SCP, SSP, Investors, Symphony Capital, RRD and Ann M. Arvin, M.D.
          “Conflict Transaction” has the meaning set forth in Article X of the
Symphony Dynamo Charter.
          “Control” means, with respect to any material, information or
intellectual property right, that a Party owns or has a license to such item or
right, and has the ability to grant the other Party access, a license or a
sublicense (as applicable) in or to such item or right as provided in the
Operative Documents without violating the terms of any agreement or other
arrangement with any third party.
          “Debt” of any Person means, without duplication:
     (a) all indebtedness of such Person for borrowed money,
     (b) all obligations of such Person for the deferred purchase price of
property or services (other than any portion of any trade payable obligation
that shall not have remained unpaid for 91 days or more from the later of
(A) the original due date of such portion and (B) the customary payment date in
the industry and relevant market for such portion),
     (c) all obligations of such Person evidenced by bonds, notes, debentures or
other similar instruments,
     (d) all obligations of such Person created or arising under any conditional
sale or other title retention agreement with respect to property acquired by
such Person (whether or not the rights and remedies of the seller or lender
under such agreement in an event of default are limited to repossession or sale
of such property),
     (e) all Capitalized Leases to which such Person is a party,
     (f) all obligations, contingent or otherwise, of such Person under
acceptance, letter of credit or similar facilities,
     (g) all obligations of such Person to purchase, redeem, retire, defease or
otherwise acquire for value any Equity Securities of such Person,
     (h) the net amount of all financial obligations of such Person in respect
of Hedge Agreements,
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

     (i) the net amount of all other financial obligations of such Person under
any contract or other agreement to which such Person is a party,
     (j) all Debt of other Persons of the type described in clauses (a) through
(i) above guaranteed, directly or indirectly, in any manner by such Person, or
in effect guaranteed, directly or indirectly, by such Person through an
agreement (A) to pay or purchase such Debt or to advance or supply funds for the
payment or purchase of such Debt, (B) to purchase, sell or lease (as lessee or
lessor) property, or to purchase or sell services, primarily for the purpose of
enabling the debtor to make payment of such Debt or to assure the holder of such
Debt against loss, (C) to supply funds to or in any other manner invest in the
debtor (including any agreement to pay for property or services irrespective of
whether such property is received or such services are rendered) or
(D) otherwise to assure a creditor against loss, and
     (k) all Debt of the type described in clauses (a) through (i) above secured
by (or for which the holder of such Debt has an existing right, contingent or
otherwise, to be secured by) any Encumbrance on property (including accounts and
contract rights) owned or held or used under lease or license by such Person,
even though such Person has not assumed or become liable for payment of such
Debt.
          “Development Budget” means the budget (comprised of the Management
Budget Component and the Clinical Budget Component) for the implementation of
the Development Plan (the initial form of which was agreed upon by Dynavax and
Symphony Dynamo as of the Closing Date and attached to the Amended and Restated
Research and Development Agreement as Annex D thereto), as may be further
developed and revised from time to time in accordance with the Development
Committee Charter and the Amended and Restated Research and Development
Agreement.
          “Development Committee” has the meaning set forth in Article 3 of the
Amended and Restated Research and Development Agreement.
          “Development Committee Charter” has the meaning set forth in Article 3
of the Amended and Restated Research and Development Agreement.
          “Development Committee Member” has the meaning set forth in
Paragraph 1 of Annex B to the Amended and Restated Research and Development
Agreement.
          “Development Plan” means the development plan covering all the
Programs (the initial form of which was agreed upon by Dynavax and Symphony
Dynamo as of the Closing Date and attached to the Amended and Restated Research
and Development Agreement as Annex C thereto), as may be further developed and
revised from time to time in accordance with the Development Committee Charter
and the Amended and Restated Research and Development Agreement.
          “Development Services” has the meaning set forth in Section 1(b) of
the RRD Services Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Director(s)” has the meaning set forth in the Preliminary Statement
of the Indemnification Agreement.
          “Disclosing Party” has the meaning set forth in Section 3 of the
Confidentiality Agreement.
          “Discontinuation Closing Date” has the meaning set forth in
Section 11.3 of the Amended and Restated Research and Development Agreement.
          “Discontinuation Date” means any date designated by Symphony Dynamo
which shall occur on or after the 90th day following the receipt by Dynavax of
notice from Symphony Dynamo of Symphony Dynamo’s intent to discontinue a Program
in accordance with the terms of the Amended and Restated Research and
Development Agreement.
          “Discontinuation Option” has the meaning set forth in Section 11.3 of
the Amended and Restated Research and Development Agreement.
          “Discontinuation Price” has the meaning set forth in Section 11.3 of
the Amended and Restated Research and Development Agreement.
          “Discontinuation Price Dispute Notice” has the meaning set forth in
Section 11.3(b) of the Amended and Restated Research and Development Agreement.
          “Discontinued Program” has the meaning set forth in Section 2.11 of
the Novated and Restated Technology License Agreement.
          “Discontinuation Program Funding” has the meaning set forth in
Section 11.3(b) of the Amended and Restated Research and Development Agreement.
          “Disinterested Directors” has the meaning set forth in Article X of
the Symphony Dynamo Charter.
          “Distribution” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.
          “Dynavax” means Dynavax Technologies Corporation, a Delaware
corporation.
          “Dynavax Common Stock” means the common stock, par value $0.001 per
share, of Dynavax.
          “Dynavax Common Stock Valuation” has the meaning set forth in Section
2(e) of the Purchase Option Agreement.
          “Dynavax Obligations” has the meaning set forth in Section 6.1 of the
Amended and Restated Research and Development Agreement.
          “Dynavax Personnel” has the meaning set forth in Section 8.4 of the
Amended and Restated Research and Development Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Dynavax Subcontractor” has the meaning set forth in Section 6.2 of
the Amended and Restated Research and Development Agreement.
          “Early Purchase Option Exercise” has the meaning set forth in
Section 1(c)(iv) of the Purchase Option Agreement.
          “Effective Registration Date” has the meaning set forth in Section
1(b) of the Registration Rights Agreement
          “Encumbrance” means (i) any security interest, pledge, mortgage, lien
(statutory or other), charge or option to purchase, lease or otherwise acquire
any interest, (ii) any adverse claim, restriction, covenant, title defect,
hypothecation, assignment, deposit arrangement, license or other encumbrance of
any kind, preference or priority, or (iii) any other security agreement or
preferential arrangement of any kind or nature whatsoever (including, without
limitation, any conditional sale or other title retention agreement).
          “Enhancements” means findings, improvements, discoveries, inventions,
additions, modifications, enhancements, derivative works, clinical development
data, or changes to the Licensed Intellectual Property and/or Regulatory Files,
in each case whether or not patentable.
          “Equity Securities” means, with respect to any Person, shares of
capital stock of (or other ownership or profit interests in) such Person,
warrants, options or other rights for the purchase or other acquisition from
such Person of shares of capital stock of (or other ownership or profit
interests in) such Person, securities convertible into or exchangeable for
shares of capital stock of (or other ownership or profit interests in) such
Person or warrants, rights or options for the purchase or other acquisition from
such Person of such shares (or such other interests), and other ownership or
profit interests in such Person (including, without limitation, partnership,
member or trust interests therein), whether voting or nonvoting, and whether or
not such shares, warrants, options, rights or other interests are authorized or
otherwise existing on any date of determination.
          “ERISA” means the United States Employee Retirement Income Security
Act of 1974, as amended.
          “Excepted Debt” has the meaning set forth in Section 5(c)(iii) of the
Purchase Option Agreement.
          “Exchange Act” means the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder.
          “Excluded ISS” means [ * ].
          “Existing NDA” has the meaning set forth in Section 2 of the
Confidentiality Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “External Directors” has the meaning set forth in the preamble of the
Confidentiality Agreement.
          “FDA” means the United States Food and Drug Administration or its
successor agency in the United States.
          “FDA Sponsor” has the meaning set forth in Section 5.1 of the Amended
and Restated Research and Development Agreement.
          “Final Discontinuation Price” has the meaning set forth in
Section 11.3(c) of the Amended and Restated Research and Development Agreement.
          “Financial Audits” has the meaning set forth in Section 6.6 of the
Amended and Restated Research and Development Agreement.
          “Financing” has the meaning set forth in the Preliminary Statement of
the Purchase Option Agreement.
          “Fiscal Year” has the meaning set forth in each Operative Document in
which it appears.
          “Form S-3” means the Registration Statement on Form S-3 as defined
under the Securities Act.
          “FTE” has the meaning set forth in Section 4.1 of the Amended and
Restated Research and Development Agreement.
          “Funding Agreement” means the Funding Agreement, dated as of the
Closing Date, among Dynavax, SCP and Investors.
          “Funding Notice” has the meaning set forth in Section 2(b) of the
Funding Agreement.
          “GAAP” means generally accepted accounting principles in effect in the
United States of America from time to time.
          “Governmental Approvals” means authorizations, consents, orders,
declarations or approvals of, or filings with, or terminations or expirations of
waiting periods imposed by any Governmental Authority.
          “Governmental Authority” means any United States or non-United States
federal, national, supranational, state, provincial, local, or similar
government, governmental, regulatory or administrative authority, agency or
commission or any court, tribunal, or judicial or arbitral body.
          “Governmental Order” means any order, writ, judgment, injunction,
decree, stipulation, determination or award entered by or with any Governmental
Authority.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Hedge Agreement” means any interest rate swap, cap or collar
agreement, interest rate future or option contract, currency swap agreement,
currency future or option contract or other similar hedging agreement.
          “Hepatitis B Products” mean [ * ].
          “Hepatitis B Program” means the identification, development,
manufacture and/or use of any Hepatitis B Products in Accordance with the
Development Plan.
          “Hepatitis C Products” mean [ * ].
          “Hepatitis C Program” means the identification, development,
manufacture and/or use of any Hepatitis C Products in Accordance with the
Development Plan.
          “Holdings” means Symphony Dynamo Holdings LLC, a Delaware limited
liability company.
          “Holdings Claims” has the meaning set forth in Section 5.01 of the
Warrant Purchase Agreement.
          “Holdings LLC Agreement” means the Amended and Restated Limited
Liability Company Agreement of Holdings, dated as of the Closing Date.
          “HSR Act Filings” means the premerger notification and report forms
required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended.
          “IND” means an Investigational New Drug Application, as described in
21 U.S.C. § 355(i)(1) and 21 C.F.R. § 312 in the regulations promulgated by the
United States Food and Drug Administration, or any foreign equivalent thereof.
          “Indemnification Agreement” means the Indemnification Agreement among
Symphony Dynamo and the Directors named therein, dated as of the Closing Date.
          “Indemnified Party” has the meaning set forth in each Operative
Document in which it appears.
          “Indemnified Proceeding” has the meaning set forth in each Operative
Document in which it appears.
          “Indemnifying Party” has the meaning set forth in each Operative
Document in which it appears.
          “Independent Accountant” has the meaning set forth in Section 11.3(c)
of the Amended and Restated Research and Development Agreement.
          “Initial Development Budget” means the initial development budget
prepared by representatives of Symphony Dynamo and Dynavax prior to the Closing
Date, and attached to the Amended and Restated Research and Development
Agreement as Annex D thereto.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Initial Development Plan” means the initial development plan prepared
by representatives of Symphony Dynamo and Dynavax prior to the Closing Date, and
attached to the Amended and Restated Research and Development Agreement as Annex
C thereto.
          “Initial Funds” has the meaning set forth in Section 2(a) of the
Funding Agreement.
          “Initial Holdings LLC Agreement” means the Agreement of Limited
Liability Company of Holdings, dated January 10, 2006.
          “Initial Investors LLC Agreement” means the Agreement of Limited
Liability Company of Investors, dated January 10, 2006.
          “Initial LLC Member” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.
          “Interest Certificate” has the meaning set forth in Section 1.01 of
the Holdings LLC Agreement.
          Investment Company Act” means the Investment Company Act of 1940, as
amended.
          “Investment Overview” means the investment overview describing the
transactions entered into pursuant to the Operative Documents.
          “Investment Policy” has the meaning set forth in Section 1(a)(vi) of
the RRD Services Agreement.
          “Investors” means Symphony Dynamo Investors LLC.
          “Investors LLC Agreement” means the Amended and Restated Agreement of
Limited Liability Company of Investors dated as of the Closing Date
          “IRS” means the U.S. Internal Revenue Service.
          “ISS” means any synthetic oligonucleotide sequence or chimeric
oligonucleotide sequence that modulates an immune response, including, but not
limited to, such sequences referred to by Dynavax as immunostimulatory
sequences, chimeric immunomodulatory compounds and branched immunomodulatory
compounds.
          “Knowledge” means the actual (and not imputed) knowledge of the
executive officers of Dynavax, without the duty of inquiry or investigation.
          “Law” means any law, statute, treaty, constitution, regulation, rule,
ordinance, order or Governmental Approval, or other governmental restriction,
requirement or determination, of or by any Governmental Authority.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “License” has the meaning set forth in the Preliminary Statement of
the Purchase Option Agreement.
          “Licensed Intellectual Property” means the Licensed Patent Rights,
Symphony Dynamo Enhancements, Licensor Enhancements and the Licensed Know-How.
          “Licensed Know-How” means [ * ].
     (a) “Licensed Patent Rights” means:[ * ].
          “Licensor” means Dynavax.
          “Licensor Enhancements” means [ * ].
          “Lien” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.
          “Liquidating Event” has the meaning set forth in Section 8.01 of the
Holdings LLC Agreement.
          “LLC Agreements” means the Initial Holdings LLC Agreement, the
Holdings LLC Agreement, the Initial Investors LLC Agreement and the Investors
LLC Agreement.
          “Loss” has the meaning set forth in each Operative Document in which
it appears.
          “Management Budget Component” has the meaning set forth in Section 4.1
of the Amended and Restated Research and Development Agreement.
          “Management Fee” has the meaning set forth in Section 6(a) of the RRD
Services Agreement.
          “Manager” means (i) for each LLC Agreement in which it appears, the
meaning set forth in such LLC Agreement, and (ii) for each other Operative
Document in which it appears, RRD.
          “Management Services” has the meaning set forth in Section 1(a) of the
RRD Services Agreement.
          “Manager Event” has the meaning set forth in Section 3.01(g) of the
Holdings LLC Agreement.
          “Material Adverse Effect” means, with respect to any Person, a
material adverse effect on (i) the business, assets, property or condition
(financial or otherwise) of such Person or, (ii) its ability to comply with and
satisfy its respective agreements and obligations under the Operative Documents
or, (iii) the enforceability of the obligations of such Person of any of the
Operative Documents to which it is a party.
          “Material Subsidiary” means, at any time, a Subsidiary of Dynavax
having assets in an amount equal to at least 5% of the amount of total
consolidated assets of Dynavax and its
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

Subsidiaries (determined as of the last day of the most recent reported fiscal
quarter of Dynavax) or revenues or net income in an amount equal to at least 5%
of the amount of total consolidated revenues or net income of Dynavax and its
Subsidiaries for the 12-month period ending on the last day of the most recent
reported fiscal quarter of Dynavax.
          “Medical Discontinuation Event” means [ * ].
          “Membership Interest” means (i) for each LLC Agreement in which it
appears, the meaning set forth in such LLC Agreement, and (ii) for each other
Operative Document in which it appears, the meaning set forth in the Holdings
LLC Agreement.
          “NASDAQ” means the National Association of Securities Dealers
Automated Quotation System.
          “NDA” means a New Drug Application, as defined in the regulations
promulgated by the United States Food and Drug Administration, or any foreign
equivalent thereof.
          “Non-Dynavax Capital Transaction” means any (i) sale or other
disposition of all or part of the Symphony Dynamo Shares or all or substantially
all of the operating assets of Symphony Dynamo, to a Person other than Dynavax
or an Affiliate of Dynavax or (ii) distribution in kind of the Symphony Dynamo
Shares following the expiration of the Purchase Option.
          “Non-Symphony Dynamo ISS” means [ * ].
          “Novated and Restated Technology License Agreement” means the Novated
and Restated Technology License Agreement, dated as of the Closing Date, among
Dynavax, Symphony Dynamo and Holdings.
          “Operative Documents” means, collectively, the Indemnification
Agreement, the Holdings LLC Agreement, the Purchase Option Agreement, the
Warrant Purchase Agreement, the Registration Rights Agreement, the Subscription
Agreement, the Technology License Agreement, the Novated and Restated Technology
License Agreement, the RRD Services Agreement, the Research and Development
Agreement, the Amended and Restated Research and Development Agreement, the
Confidentiality Agreement, the Funding Agreement and each other certificate and
agreement executed in connection with any of the foregoing documents.
          “Organizational Documents” means any certificates or articles of
incorporation or formation, partnership agreements, trust instruments, bylaws or
other governing documents.
          “Partial Stock Payment” has the meaning set forth in Section 3(a)(iii)
of the Purchase Option Agreement.
          “Party(ies)” means, for each Operative Document or other agreement in
which it appears, the parties to such Operative Document or other agreement, as
set forth therein. With respect to any agreement in which a provision is
included therein by reference to a provision in
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

another agreement, the term “Party” shall be read to refer to the parties to the
document at hand, not the agreement that is referenced.
          “Payment Terms” has the meaning set forth in Section 8.2 of the
Amended and Restated Research and Development Agreement.
          “Percentage” has the meaning set forth in Section 1.01 of the Holdings
LLC Agreement.
          “Permitted Investments” has the meaning set forth in Section 1.01 of
the Holdings LLC Agreement.
          “Permitted Lien” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.
          “Person” means any individual, partnership (whether general or
limited), limited liability company, corporation, trust, estate, association,
nominee or other entity.
          “Personnel” of a Party means such Party, its employees,
subcontractors, consultants, representatives and agents.
          “Prime Rate” means the quoted “Prime Rate” at JPMorgan Chase Bank or,
if such bank ceases to exist or is not quoting a base rate, prime rate reference
rate or similar rate for United States dollar loans, such other major money
center commercial bank in New York City selected by the Manager.
          “Products” means Cancer Products, Hepatitis B Products and Hepatitis C
Products.
          “Profit” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.
          “Program Option” has the meaning set forth in Section 11.1(a) of the
Amended and Restated Research and Development Agreement.
          “Program Option Closing Date” has the meaning set forth in
Section 11.1(b) of the Amended and Restated Research and Development Agreement.
          “Program Option Exercise Date” has the meaning set forth in
Section 11.1(b) of the Amended and Restated Research and Development Agreement.
          “Program Option Exercise Notice” has the meaning set forth in
Section 11.1(b) of the Amended and Restated Research and Development Agreement.
          “Program Option Period” has the meaning set forth in Section 11.1(a)
of the Amended and Restated Research and Development Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Programs” means Cancer Program, Hepatitis B Program and Hepatitis C
Program.
          “Protocol” means a written protocol that meets the substantive
requirements of Section 6 of the ICH Guideline for Good Clinical Practice as
adopted by the FDA, effective May 9, 1997 and is included within the Development
Plan or later modified or added to the Development Plan pursuant to the Amended
and Restated Research and Development Agreement.
          “Public Companies” has the meaning set forth in Section 5(e) of the
Purchase Option Agreement.
          “Purchase Option” has the meaning set forth in Section 1(a) of the
Purchase Option Agreement.
          “Purchase Option Agreement” means this Purchase Option Agreement dated
as of the Closing Date, among Dynavax, Holdings and Symphony Dynamo.
          “Purchase Option Closing” has the meaning set forth in Section 2(a) of
the Purchase Option Agreement.
          “Purchase Option Closing Date” has the meaning set forth in Section
2(a) of the Purchase Option Agreement.
          “Purchase Option Commencement Date” has the meaning set forth in
Section 1(c)(iii) of the Purchase Option Agreement.
          “Purchase Option Exercise Date” has the meaning set forth in Section
2(a) of the Purchase Option Agreement.
          “Purchase Option Exercise Notice” has the meaning set forth in Section
2(a) of the Purchase Option Agreement.
          “Purchase Option Interim Date” has the meaning set forth in
Section 2(b)(i) of the Purchase Option Agreement.
          “Purchase Option Period” has the meaning set forth in
Section 1(c)(iii) of the Purchase Option Agreement.
          “Purchase Price” has the meaning set forth in Section 2(b) of the
Purchase Option Agreement.
          “Put Option” has the meaning set forth in Section 2A of the Purchase
Option Agreement.
          “Put Option Exercise Notice” has the meaning set forth in Section 2A
of the Purchase Option Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “QA Audits” has the meaning set forth in Section 6.5 of the Amended
and Restated Research and Development Agreement.
          “Quarterly Price” has the meaning set forth in Section 2(b)(i) of the
Purchase Option Agreement.
          “Regents” has the meaning set forth in Section 3.1 of the Novated and
Restated Technology License Agreement.
          “Regents Agreement” has the meaning set forth in Section 3.1 of the
Novated and Restated Technology License Agreement.
          “Registration Rights Agreement” means the Registration Rights
Agreement dated as of the Closing Date, between Dynavax and Holdings.
          “Registration Statement” has the meaning set forth in Section 1(b) of
the Registration Rights Agreement.
          “Regulatory Authority” means the United States Food and Drug
Administration, or any successor agency in the United States, or any health
regulatory authority(ies) in any other country that is a counterpart to the FDA
and has responsibility for granting registrations or other regulatory approval
for the marketing, manufacture, storage, sale or use of drugs in such other
country.
          “Regulatory Allocation” has the meaning set forth in Section 3.06 of
the Holdings LLC Agreement.
          “Regulatory Files” means any IND, NDA or any other filings filed with
any Regulatory Authority with respect to the Programs.
          “Related Oncology Products Agreement” has the meaning set forth in
Section 11.4 of the Amended and Restated Research and Development Agreement.
          “Replacement Warrant(s)” has the meaning set forth in Section 7.08 of
the Warrant Purchase Agreement.
          “Representative” of any Person means such Person’s shareholders,
principals, directors, officers, employees, members, managers and/or partners.
          “Research and Development Agreement” means the Research and
Development Agreement dated as of the Closing Date, between Dynavax and
Holdings.
          “Rhein” has the meaning set forth in Section 11.1(a) of the Amended
and Restated Research and Development Agreement.
          “Rhein Sale Agreement” has the meaning set forth in Section 11.2(a) of
the Amended and Restated Research and Development Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “RRD” means RRD International, LLC, a Delaware limited liability
company.
          “RRD Indemnified Party” has the meaning set forth in Section 10(a) of
the RRD Services Agreement.
          “RRD Loss” has the meaning set forth in Section 10(a) of the RRD
Services Agreement.
          “RRD Parties” has the meaning set forth in Section 9(e) of the RRD
Services Agreement.
          “RRD Personnel” has the meaning set forth in Section 1(a)(ii) of the
RRD Services Agreement.
          “RRD Services Agreement” means the RRD Services Agreement between
Symphony Dynamo and RRD, dated as the Closing Date, 2006.
          “Schedule K-1” has the meaning set forth in Section 9.02(a) of the
Holdings LLC Agreement.
          “Scheduled Meeting” has the meaning set forth in Paragraph 6 of Annex
B of the Amended and Restated Research and Development Agreement.
          “Scientific Discontinuation Event” has the meaning set forth in
Section 4.2(c) of the Amended and Restated Research and Development Agreement.
          “SCP” means Symphony Capital Partners, L.P., a Delaware limited
partnership.
          “SD Program Option” has the meaning set forth in Section 11.2(b) of
the Amended and Restated Research and Development Agreement.
          “SD Program Option Exercise Notice” has the meaning set forth in
Section 11.2(b) of the Amended and Restated Research and Development Agreement.
          “SEC” means the United States Securities and Exchange Commission.
          “Securities Act” means the Securities Act of 1933, as amended.
          “Selected ISS” means [ * ].
          “Shareholder” means any Person who owns any Symphony Dynamo Shares.
          “Solvent” has the meaning set forth in Section 1.01 of the Holdings
LLC Agreement.
          “SSP” means Symphony Strategic Partners, LLC, a Delaware limited
liability company.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Stock Payment Date” has the meaning set forth in Section 2 of the
Subscription Agreement.
          “Stock Purchase Price” has the meaning set forth in Section 2 of the
Subscription Agreement.
          “Subcontracting Agreement” has the meaning set forth in Section 6.2 of
the Amended and Restated Research and Development Agreement.
          “Subscription Agreement” means the Subscription Agreement between
Symphony Dynamo and Holdings, dated as the Closing Date.
          “Subsidiary” of any Person means any corporation, partnership, joint
venture, limited liability company, trust or estate of which (or in which) more
than 50% of (a) the issued and outstanding capital stock having ordinary voting
power to elect a majority of the board of directors of such corporation
(irrespective of whether at the time capital stock of any other class or classes
of such corporation shall or might have voting power upon the occurrence of any
contingency); (b) the interest in the capital or profits of such partnership,
joint venture or limited liability company; or (c) the beneficial interest in
such trust or estate is at the time directly or indirectly owned or controlled
by such Person, by such Person and one or more of its other Subsidiaries or by
one or more of such Person’s other Subsidiaries.
          “Surviving Entity” means the surviving or resulting “parent” legal
entity which is surviving entity to Dynavax after giving effect to a Change of
Control.
          “Symphony Capital” means Symphony Capital LLC, a Delaware limited
liability company.
          “Symphony Dynamo” means Symphony Dynamo, Inc., a Delaware corporation.
          “Symphony Dynamo Auditors” has the meaning set forth in Section 5(b)
of the RRD Services Agreement.
          “Symphony Dynamo Board” means the board of directors of Symphony
Dynamo.
          “Symphony Dynamo By-laws” means the By-laws of Symphony Dynamo, as
adopted by resolution of the Symphony Dynamo Board on the Closing Date.
          “Symphony Dynamo Charter” means the Amended and Restated Certificate
of Incorporation of Symphony Dynamo, dated as of the Closing Date.
          “Symphony Dynamo Director Event” has the meaning set forth in
Section 3.01(h)(i) of the Holdings LLC Agreement.
          “Symphony Dynamo Enhancements” means [ * ].
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Symphony Dynamo Equity Securities” means the Common Stock and any
other stock or shares issued by Symphony Dynamo.
          “Symphony Dynamo Loss” has the meaning set forth in Section 10(b) of
the RRD Services Agreement.
          “Symphony Dynamo Shares” has the meaning set forth in Section 2.02 of
the Holdings LLC Agreement.
          “Symphony Fund(s)” means Symphony Capital Partners, L.P., a Delaware
limited partnership, and Symphony Strategic Partners, LLC, a Delaware limited
liability company.
          “Tangible Materials” means [ * ].
          “Tax Amount” has the meaning set forth in Section 4.02 of the Holdings
LLC Agreement.
          “Technology License Agreement” means the Technology License Agreement,
dated as of the Closing Date, between Dynavax and Holdings.
          “Term” has the meaning set forth in Section 4(b)(iii) of the Purchase
Option Agreement, unless otherwise stated in any Operative Document.
          “Territory” means the world.
          “Third Party IP” has the meaning set forth in Section 2.11 of the
Novated and Restated Technology License Agreement.
          “Third Party Licensor” means a third party from which Dynavax has
received a license or sublicense to Licensed Intellectual Property.
          “Transfer” has for each Operative Document in which it appears the
meaning set forth in such Operative Document.
          “Transferee” has, for each Operative Document in which it appears, the
meaning set forth in such Operative Document.
          “Voluntary Bankruptcy” has the meaning set forth in Section 1.01 of
the Holdings LLC Agreement.
          “Warrant(s)” means the “Warrant” as defined in Section 2.01 of the
Warrant Purchase Agreement, and/or any successor certificates exercisable for
Warrant Shares issued by Dynavax.
          “Warrant Closing” has the meaning set forth in Section 2.03 of the
Warrant Purchase Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

          “Warrant Date” has the meaning set forth in Section 2.02 of the
Warrant Purchase Agreement.
          “Warrant Purchase Agreement” means the Warrant Purchase Agreement,
dated as of the Closing Date, between Dynavax and Holdings.
          “Warrant Shares” has the meaning set forth in Section 2.01 of the
Warrant Purchase Agreement.
          “Warrant Surrender Price” has the meaning set forth in Section 7.08 of
the Warrant Purchase Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

EXHIBIT 1
PURCHASE OPTION EXERCISE NOTICE
[ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

EXHIBIT 2
FORM OF OPINION COOLEY GODWARD LLP
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

(COOLEY GODWARD LLP) [f22482f2248201.gif]

         
 
  ATTORNEYS AT LAW   Broomfield, CO
 
      720 566-4000
 
  Five Palo Alto Square   Reston, VA
 
  3000 El Camino Real   703 456-8000
 
  Palo Alto, CA   San Diego, CA
 
  94306-2155   858 550-6000
 
  Main 650 843-5000   San Francisco, CA
 
  Fax 650 849-7400   415 693-2000
 
       
 
  www.cooley.com    

April 18, 2006
Symphony Dynamo Holdings LLC
7361 Calhoun Place, Suite 325
Rockville, MD 20850
Dear Ladies and Gentlemen:
We have acted as counsel for Dynavax Technologies Corporation, a Delaware
corporation (the “Company”), in connection with the financing of certain of the
Company’s research and development programs (the “Financing”). In connection
with the Financing, the Company is entering into the agreements listed on
Schedule I hereto (collectively, the “Transaction Agreements”). We are rendering
this opinion pursuant to Section 3.02(d) of the Warrant Purchase Agreement.
In connection with this opinion, we have examined and relied upon the
representations and warranties as to factual matters contained in and made
pursuant to the Transaction Agreements by the various parties and originals, or
copies certified to our satisfaction, of such records, documents, certificates,
opinions, memoranda and other instruments as in our judgment are necessary or
appropriate to enable us to render the opinion expressed below.
As to certain factual matters, we have relied upon certificates of officers of
the Company and have not sought to independently verify such matters. Where we
render an opinion “to our knowledge” or concerning an item “known to us” or our
opinion otherwise refers to our knowledge, it is based solely upon (i) an
inquiry of attorneys within this firm who have represented the Company in this
transaction, (ii) receipt of a certificate executed by an officer of the Company
covering such matters and (iii) such other investigation, if any, that we
specifically set forth herein.
In rendering this opinion, we have assumed: the authenticity of all documents
submitted to us as originals; the conformity to originals of all documents
submitted to us as copies; the accuracy, completeness and authenticity of
certificates of public officials; the due authorization, execution and delivery
of all documents (except the due authorization, execution and delivery by the
Company of the Transaction Agreements), where authorization, execution and
delivery are prerequisites to the effectiveness of such documents; and the
genuineness and authenticity of all signatures on original documents (except the
signatures on behalf of the Company on the Transaction Agreements). We have also
assumed: that all individuals executing and delivering documents had the legal
capacity to so execute and deliver; that the Transaction Agreements are
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

Symphony Dynamo Holdings LLC
Page 4
obligations binding upon the parties thereto other than the Company; that the
parties to the Transaction Agreements other than the Company have filed any
required California franchise or income tax returns and have paid any required
California franchise or income taxes; and that there are no extrinsic agreements
or understandings among the parties to the Transaction Agreements or to the
Material Agreements (as defined below) that would modify or interpret the terms
of any such agreements or the respective rights or obligations of the parties
thereunder.
Our opinion is expressed only with respect to the federal laws of the United
States of America and the laws of the State of California and the General
Corporation Law of the State of Delaware. We note that the parties to the
Transaction Agreements have designated the laws of the State of New York as the
laws governing the Transaction Agreements. Our opinion in paragraph 6 below as
to the validity, binding effect and enforceability of the Transaction Agreements
is premised upon the result that would obtain if a California court were to
apply the internal laws of the State of California (notwithstanding the
designation of the laws of the State of New York) to the interpretation and
enforcement of the Transaction Agreements. We express no opinion as to whether
the laws of any particular jurisdiction apply, and no opinion to the extent that
the laws of any jurisdiction other than those identified above are applicable to
the subject matter hereof, and we have not obtained any opinion of counsel under
the laws of the State of New York.
We are not rendering any opinion as to any statute, rule, regulation, ordinance,
decree or decisional law relating to antitrust, banking, land use,
environmental, pension, employee benefit, tax, fraudulent conveyance, usury,
laws governing the legality of investments for regulated entities, regulations
T, U or X of the Board of Governors of the Federal Reserve System or local law.
Furthermore, we express no opinion with respect to compliance with antifraud
laws, rules or regulations relating to securities or the offer and sale thereof;
compliance with fiduciary duties by the Company’s Board of Directors or
stockholders; compliance with safe harbors for disinterested Board of Director
or stockholder approvals; compliance with state securities or blue sky laws
except as specifically set forth below; or compliance with laws that place
limitations on corporate distributions.
With regard to our opinion in paragraph 1 below, we have relied solely upon a
certificate of the Secretary of State of the State of Delaware as of a recent
date.
With regard to our opinion in paragraph 3 below, with respect to the due and
valid authorization of each of the Transaction Documents, we have relied solely
upon (i) a certificate of an officer of the Company, (ii) a review of the
certificate of incorporation and bylaws of the Company, (iii) a review of the
resolutions certified by an officer of the Company, (iv) and a review of the
Delaware General Corporation Law.
With regard to our opinion paragraph 4 below concerning material defaults under
and any material breaches of any agreement identified on Schedule II hereto, we
have relied solely upon
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

Symphony Dynamo Holdings LLC
Page 5
(i) a certificate of an officer of the Company, (ii) a list supplied to us by
the Company of material agreements to which the Company is a party, or by which
it is bound, a copy of which is attached hereto as Schedule II (the “Material
Agreements”) and (iii) an examination of the Material Agreements in the form
provided to us by the Company. We have made no further investigation. Further,
with regard to our opinion in paragraph 4 below concerning Material Agreements,
we express no opinion as to (i) financial covenants or similar provisions
therein requiring financial calculations or determinations to ascertain
compliance, (ii) provisions therein relating to the occurrence of a “material
adverse event” or words of similar import or (iii) any statement or writing that
may constitute parol evidence bearing on interpretation or construction.
With regard to our opinion in paragraph 7 below, we express no opinion to the
extent that, notwithstanding its current reservation of shares of Common Stock,
future issuances of securities of the Company and/or antidilution adjustments to
outstanding securities of the Company may cause the Warrant Shares or the
Dynavax Common Stock to exceed the number of shares of Common Stock that then
remain authorized but unissued.
With regard to our opinion in paragraph 8 concerning exemption from
registration, our opinion is expressed only with respect to the offer and sale
of the Warrant or the Warrant Shares without regard to any offers or sales of
securities occurring prior to or subsequent to the date hereof.
With regard to our opinion in paragraph 9 below, we have based our opinion, to
the extent we consider appropriate, on Rule 3a-8 under the Investment Company
Act of 1940, as amended, and a certificate of an officer of the Company as to
compliance with each of the requirements necessary to comply with Rule 3a-8. We
have conducted no further investigation.
On the basis of the foregoing, in reliance thereon and with the foregoing
qualifications, we are of the opinion that:

1.   The Company has been duly incorporated and is a validly existing
corporation in good standing under the laws of the State of Delaware.

2.   The Company has the corporate power to execute, deliver and perform its
obligations under the Transaction Agreements.

3.   Each of the Transaction Agreements has been duly and validly authorized,
executed and delivered by the Company. The offer and sale of the Warrant (as
defined in the Warrant Purchase Agreement) has been duly authorized by the
Company.

4.   The execution and delivery of the Transaction Agreements by the Company and
the issuance of the Warrant pursuant thereto and the Warrant Shares assuming the
exercise of the Warrant on the date hereof, will not, (a) violate any provision
of the Company’s certificate of incorporation or by-laws, (b) violate any
governmental statute, rule or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

Symphony Dynamo Holdings LLC
Page 6

    regulation which in our experience is typically applicable to transactions
of the nature contemplated by the Transaction Agreements, (c) violate any order,
writ, judgment, injunction, decree, determination or award which has been
entered against the Company and of which we are aware or (d) constitute a
material default under or a material breach of any Material Agreement, in the
case of clauses (c) and (d) to the extent such default or breach would
materially and adversely affect the Company.   5.   All consents, approvals,
authorizations or orders of, and filings, registrations and qualifications with
any U.S. Federal or California regulatory authority or governmental body
required for the due execution or delivery by the Company of any Transaction
Agreement and the sale and issuance of the Warrant have been made or obtained,
except (a) for the filing of a Form D pursuant to Securities and Exchange
Commission Regulation D and (b) for the filing of the notice to be filed under
California Corporations Code Section 25102.1(d).   6.   Each of the Transaction
Agreements constitutes a valid and binding agreement of the Company, enforceable
against the Company in accordance with its respective terms, except as rights to
indemnity and contribution under Sections 6 and 7 of the Registration Rights
Agreement, Section 10 of the Purchase Option Agreement, Article V of the Warrant
Purchase Agreement, Section 15 of the Research and Development Agreement,
Section 15 of the Amended and Restated Research and Development Agreement,
Section 6 of the Technology License Agreement and Section 6 of the Novated and
Restated Technology License Agreement may be limited by applicable laws and
except as enforcement may be limited by applicable bankruptcy, insolvency,
reorganization, arrangement, suretyship, dissolution, moratorium, receivership
or other similar laws affecting creditors’ rights and the law of fraudulent
transfer, and subject to state law, federal law, or general equity principles
and to limitations on availability of equitable relief, including specific
performance, regardless of whether enforcement is considered in a proceeding in
equity or at law.   7.   The Warrant Shares (as defined in the Warrant Purchase
Agreement) and, the Dynavax Common Stock (as defined in the Purchase Option
Agreement), when sold and issued in accordance with the terms of the Warrant or
the Purchase Option Agreement, as applicable, will be validly issued, fully paid
and non-assessable, and the issuance of the Warrant Shares is not be subject to
preemptive rights pursuant to the General Corporation Law of the State of
Delaware, the certificate of incorporation or by-laws of the Company or similar
rights to subscribe pursuant to any Material Agreement.   8.   The offer and
sale of the Warrant and Warrant Shares (assuming exercise of the Warrant on the
date hereof) are exempt from the registration requirements of the Securities Act
of

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

Symphony Dynamo Holdings LLC
Page 7

    1933, as amended, subject to the timely filing of a Form D pursuant to
Securities and Exchange Commission Regulation D.   9.   The Company is not an
“investment company” as defined in the Investment Company Act of 1940, as
amended.

[ * ]
This opinion is intended solely for your benefit and is not to be made available
to or be relied upon by any other person, firm, or entity without our prior
written consent.
Very truly yours,
Cooley Godward LLP

         
By:
  /s/ Robert L. Jones    
 
       
 
  Robert L. Jones    

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

Schedule I
List of Transaction Agreements

i.   Warrant Purchase Agreement, dated as of April 18, 2006 between the Company
and Symphony Dynamo Holdings LLC (the “Warrant Purchase Agreement”).   ii.  
Warrant to purchase 2,000,000 shares of common stock of the Company, dated as of
April 18, 2006 (the “Warrant”).   iii.   Purchase Option Agreement, dated as of
April 18, 2006, among the Company, Symphony Dynamo Holdings LLC and Symphony
Dynamo, Inc. (the “Purchase Option Agreement”).   iv.   Research and Development
Agreement, dated as of April 18, 2006, between the Company and Symphony Dynamo
Holdings LLC (the “Research and Development Agreement”).   v.   Amended &
Restated Research and Development Agreement, dated as of April 18, 2006 among
the Company, Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC (the
“Amended & Restated Research and Development Agreement”).   vi.   Technology
License Agreement, dated as of April 18, 2006 between the Company and Symphony
Dynamo Holdings LLC (the “Technology License Agreement”). vii. Novated and
Restated Technology License Agreement, dated as of April 18, 2006, among the
Company, Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC (the “Novated
and Restated Technology License Agreement”).   viii.   Confidentiality
Agreement, dated as of April 18, 2006, among the Company, Symphony Dynamo, Inc.,
Symphony Dynamo Holdings LLC, Symphony Capital Partners, L.P., Symphony
Strategic Partners, LLC, Symphony Dynamo Investors LLC, Symphony Capital LLC,
RRD International, LLC, and Ann M. Arvin, M.D. (the “Confidentiality
Agreement”).   ix.   Funding Agreement, dated as of April 18, 2006, among the
Company, Symphony Capital Partners, L.P., Symphony Dynamo Holdings LLC and
Symphony Dynamo Investors, LLC (the “Funding Agreement”).   x.   Registration
Rights Agreement, dated as of April 18, 2006, between the Company and Symphony
Dynamo Holdings LLC (the “Registration Rights Agreement”).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

 

--------------------------------------------------------------------------------

 

Schedule II
List of Material Agreements
[ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.